ORIGINAL_ARTICLE
Role of Immunohistochemistry in the Diagnosis of Solitary Fibrous Tumor, a Review
Background: Solitary fibrous tumor (SFT) is a mesenchymal tumor which is most commonly seen in the pleura; however it can be seen in other organs such as the meninge, gastrointestinal tract, soft tissue, bone, and skin. SFT should be differentiated from other mesenchymal tumors in these organs. Immunohistochemistry plays a pivotal role for the histopathologic diagnosis of this tumor. Currently, new markers have been introduced which has been very useful for definite diagnosis of SFT along with other markers in each specific location which are negative in SFT. Methods: Here we review the reported positive and negative immunohistochemical markers of SFT in the English literature with the emphasis on the useful markers in each specific organ. We explored the English literature from 1990 through 2015 via PubMed, Google, and Google scholar using the following search keywords: Solitary fibrous tumor, Solitary fibrous tumor and immunohistochemistry, Solitary fibrous tumor and diagnosis, Solitary fibrous tumor and histogenesis, Solitary fibrous tumor and prognosis, Solitary fibrous tumor and hemangiopericytoma, Solitary fibrous tumor and differential diagnosis, Solitary fibrous tumor and markers. Results: The most important and valuable positive markers in SFT are CD34, CD99, Bcl-2 and STAT-6.There are consistently negative markers in this tumor as well, used according to the tumor location, such as EMA and S100 Conclusion: Immunohistochemistry is very useful for the diagnosis of solitary fibrous tumor and for its differentiation with other spindle cell mesenchymal tumor in different locations.
How to cite this article:
Geramizadeh B, Marzban M, Churg A. Role of Immunohistochemistry in the Diagnosis of Solitary Fibrous Tumor, a Review. Iran J Pathol. 2016; 11(3):195-293.
https://ijp.iranpath.org/article_19723_2d0e9efd0ea84ddf21f877b9852bbeea.pdf
2016-07-01
195
203
Solitary Fibrous Tumor
Immunohistochemistry
Bita
Geramizadeh
geramib@sums.ac.ir
1
Dept. of Pathology, Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
LEAD_AUTHOR
Mahsa
Marzban
geramib1@gmail.com
2
University of British Columbia, Vancouver, BC, Canada
AUTHOR
Andrew
Churg
3
Dept. of Pathology, Vancouver General Hospital and University of British Columbia, Vancouver , BC, Canada
AUTHOR
Wagner E. Das tuberkelähnliche Lymphadenom. (Der cytogene oder reticulirte Tuberkel). Leipzig: O. Wigand; 1871.
1
Klemperer P, Coleman BR. Primary neoplasms of the pleura. A report of five cases. Am J Ind Med 1992; 22(1):1-31.
2
Guo W, Xiao HL, Jiang YG, Wang RW, Zhao YP, Ma Z, et al. Retrospective analysis for thirty-nine patients with solitary fibrous tumor of pleura and review of the literature. World J Surg Oncol 2011;9: 134-140.
3
Fletcher C DM, Bridge JA, Lee JC. Extrapleural solitary fibrous tumor. World Health Organization Classification of Tumors of Soft Tissue and Bone. Lyon, France: IARC Press; 2013; 81.
4
Geramizadeh B, Banani A, Moradi A, Hosseini SMV. Intrapulmonary solitary fibrous tumor with bronchial involvement: a rare case report in a child. J Pediat Surg 2010; 45(1): 249–251.
5
DeVito N, Henderson E, Han G,Reed D, Bui MM, Lavey R, et al. Clinical characteristics and outcomes for solitary fibrous tumor (SFT): A Single center experience. PLoS One 10(10): e0140362
6
Hsieh TY, Chang Chien YC, Chen WH, Chen SC, Chang LC, Hwang CC, Chein HP, Chen JR. De novo malignant solitary fibrous tumor of the kidney. Diagn Pathol 2011;6: 96-102.
7
Rakheis D, Molberg KH, Roberts CA, Jaiswal VR. Immunohistochemical Expression of β-Catenin in Solitary Fibrous Tumors. Arch Pathol Lab Med 2005; 129 (6):776–779.
8
Vogels RJ, Vlenterie M, Versleijen-Jonkers YMH, Ruijter E, Bekers EM,Verdijk MAJ, et al. Solitary fibrous tumor – clinicopathologic, immunohistochemical and molecular analysis of 28 cases. Diagn Pathol 2014;9:224-33.
9
Dagrada GP, Spagnuolo RD, Mauro V, Tamborini E, Cesana L, Gronchi A, et al. Solitary fibrous tumors: loss of chimeric protein expression and genomic instability mark dedifferentiation. Mod Pathol 2015; 28(8): 1074–1083.
10
Akaike K, Kurisaki-Arakawa A, Hara K, Suehara Y, Takagi T, MT KM, et al.Distinct clinicopathological features of NAB2-STAT6 fusion gene variants in solitary fibrous tumor with emphasis on the acquisition of highly malignant potential. Hum Pathol 2015; 46(3): 347–356.
11
Wang H, Chen P, Zhao W, Shi L, Gu X, Xu Q. Clinicopathological findings in a case series of abdominopelvic solitary fibrous tumors. Oncol Lett 2014; 7(4): 1067-1072.
12
Yoshida A, Tsuta k, Ohno M, Yoshida M, Narita y, Kawai A, et al. STAT6 Immunohistochemistry Is Helpful in the Diagnosis of Solitary Fibrous Tumors. Am J Surg Pathol 2014;38(4): 552–559.
13
Koelsche C, Schweizer L, Renner M, Warth A, Jones DTW, Sahm F, et al. Nuclear relocation of STAT6 reliably predicts NAB2–STAT6 fusion for the diagnosis of solitary fibrous tumour. Histopathology 2014; 65(5):613-622.
14
Bauer JL, Miklos AZ, Thompson LDR. Parotid Gland Solitary Fibrous Tumor: A Case Report and Clinicopathologic Review of 22 Cases from the Literature. Head and Neck Pathol 2012; 6(1):21–31.
15
Mohajeri A,Tayebwa J, Collin A,Nilsson j,Magnusson l,Vult von Steyern F, et al. Comprehensive Genetic Analysis Identifies a Pathognomonic NAB2/STAT6 Fusion Gene, Nonrandom Secondary Genomic Imbalances, and a Characteristic Gene Expression Profile in Solitary Fibrous Tumor. Genes Chromosomes Cancer 2013;52 (10):873–886.
16
Barthelme S,Geddert H, Boltze C, Moskalev EA, Bieg M, Sirbu H, et al.Solitary Fibrous tumors/hemangiopericytomas with different variants of the NAB2-STAT6 gene fusion are characterized by specific histomorphology and distinct clinicopathological features. Am J Pathol 2014;184(4): 1209-18.
17
Jadczak P,Guz W, Kaznowska E,Ramotowski R,Szalacha-Tarała,Górecki A, Samojedny A. Solitary Fibrous Tumour of the Pleura – Cases Analysis. Pol J Radiol 2014;79: 368-373 .
18
Karpathiou G, Stefanou D, Froudarakis ME. Pleural neoplastic pathology. Respir Med 2015; 109 (8) :931-43.
19
Morgab MB, Smoller BR. Solitary fibrous tumors are immunophenotypically distinct from mesothelioma(s). J Cutan Pathol 2000;27(9):451-54.
20
Yokoi T, Tsuzuki T, Yatabe y, Suzuki M, Kurumaya H, Koshikawa T, et al. Solitary fibrous tumor: Significance of P53 and CD34 immunoreactivity in its malignant transformation. Histopathology 1998;32(5):423-32.
21
Schirosi L, Lantuejoul S, Cavazza A, Murer B, Brichon PY, Migaldi M,et al. Pleuro-pulmonary solitary fibrous tumors. A clinicopathologic, immunohistochemical, and molecular study of 88 cases confirming the prognostic value of de Perrot staging system and p53 expression, and evaluating the role of c-kit, BRAF, PDGFRs (a/b), c-met, and EGFR. Am J Surg Pathol 2008;32(11):1627-1642.
22
Barak S, Wang Z Miettinen M. Immunoreactivity for calretinin and keratins in desmoid fibromatosis and other myofibroblastic tumors. A diagnostic pitfall. Am J Surg Pathol 2012;36(9):1404–1409.
23
Naito Y, Ishii G, Kawai O, Hasebe T, Nishiwaki Y, Nagai K and et al. D2-40-positive solitary fibrous tumors of the pleura: Diagnostic pitfall of biopsy specimen. Pathol Int 2007;57:618-21.
24
Rao N, Colby TV, Falconieri G, Cohen H, Moran CA, Suster S.Intrapulmonary Solitary Fibrous Tumors Clinicopathologic and Immunohistochemical Study of 24 Cases. Am J Surg Pathol 2013;37(2):155-166.
25
Kouki HS, Koletsis EN, Zolota V, Prokakis C, Apostolakis E, Dougenis D. Solitary fibrous tumor of the lung. Gen Thorac Cardiovasc Surg 2008;56(5):249-251.
26
Suzuki SO, Fukul M, Nlshlo S, Iwakl T. Clinicopathological features of solitary fibrous tumor of the meninges: An immunohistochemical reappraisal of cases previously diagnosed to be fibrous meningioma or hemangiopericytoma. Pathol Int 2000;50(10):808-817.
27
Bosman F, Jaffe E, Lakhani S, Ohgaki H. WHO classification of tumors of central nervous system. IARC Press, Lyon , 2013.
28
Schweizer L, Koelsche C, Sahm F,Piro RM,Capper D, Reuss DE, et al. Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. Acta Neuropath 2013;125(5):651-8.
29
Bouvier C, Métellus P, de Paula AM, Vasiljevic A, Jouvet A, Guyotat J, et al.Solitary Fibrous Tumors and Hemangiopericytomas of the Meninges: Overlapping Pathological Features and Common Prognostic Factors Suggest the Same Spectrum of Tumors. Brain Pathol 2012;22(4):511-521.
30
Mekni A, Kourda J, Ben Hammouda K, Tangour M, Kchir N, Zitouna M, et al. Solitary fibrous tumour of the central nervous system: pathological study of eight cases and review of the literature. Pathology 2009;41(7):649-54.
31
Hayashia Y,Uchiyamaa N, Hayashia Y, Nakadaa M, Iwatoa M. A re-evaluation of the primary diagnosis of hemangiopericytoma and the clinical importance of differential diagnosis from solitary fibrous tumor of the central nervous system. Clin Neurol Neurosurg 2009;111(1):34-8
32
Bisceglia M, Galliani C, Giannatempo G, Lauriola W, Bianco M, D’Angelo V, et al .Solitary Fibrous Tumor of the Central Nervous System:A 15-year Literature Survey of 220 Cases. Adv Anat pathol 2011; 18(5):356-92.
33
Hah HP, Bundock EA, Hornick JL, .Immunohistochemical Staining for Claudin-1 Can Help Distinguish Meningiomas from Histologic Mimics. Am J Clin Pathol 2006; 125(2):203-208.
34
Chen H, Zeng XW, Wu JS, Dou YF, Wang Y, Zhong P, et al. Solitary fibrous tumor of the central nervous system: a clinicopathologic study of 24 cases. Acta Neurochir (Wien). 2012;154(2):237-48
35
Ambrosini-Spaltro A, Eusebi V. Meningeal hemangiopericytomas and hemangiopericytoma /solitary fibrous tumors of extracranial soft tissues: a comparison. Virchows Arch 2010;456 (4): 343-354.
36
Verbeke SL, Fletcher CD, Alberghini M, Daugaard S, Flamagan AM, Hogendoom CW, et al. A Reappraisal of Hemangiopericytoma of Bone; Analysis of Cases Reclassified as Synovial Sarcoma and Solitary Fibrous Tumor of Bone. Am J Surg Pathol 2010;34(6):777-783.
37
Cheah AL, Billings SD, Goldblum JR, Carver P, Tanas MZ, Rubin BP. STAT6 rabbit monoclonal antibody is a robust diagnostic tool for the distinction of solitary fibrous tumour from its mimics. Pathology 2014;46(5): 389-95.
38
Demicco EG, Harms PW, Patel RM, Smith SC, Ingram D, Torres K, et al. Extensive Survey of STAT6 Expression in a Large Series of Mesenchymal Tumors. Am J Clin Pathol 2015;143(5):672-82.
39
Vivero M, Doyle LA, Fletcher CD, Mertens F, Hornick JL. GRIA2 is a novel diagnostic marker for solitary fibrous tumour identified through gene expression profiling. Histopathology 2014;65(7):71-80.
40
Erday G, Qureshi HS, Patterson JW, Wick MR. Solitary fibrous tumors of the skin: a clinicopathologic study of 10 cases and review of the literature. J Cut Pathol 2007;34(11):844-850.
41
Carlson JW, Fletcher CDM. Immunohistochemistry for β-catenin in the differential diagnosis of spindle cell lesions: analysis of a series and review of the literature. Histopathology 2007;51(4):509-14.
42
Wood L, Fountaine TJ, Rosamilia L, Helm KF, Clarke LE. Cutaneous CD34+ Spindle Cell Neoplasms: Histopathologic Features Distinguish Spindle Cell Lipoma, Solitary Fibrous Tumor, and Dermatofibrosarcoma Protuberans. Am J Dematopathol 2010;32(8):764-768.
43
Turner MS, Goldsmith JD. Best Practices in Diagnostic Immunohistochemistry. Spindle Cell Neoplasms of the Gastrointestinal Tract. Arch Pathol Lab Med 2009;133(9):1370-74.
44
Shidham VB, Chivukula M, Gupta D, Nagarjun R, Komorowski R. Immunohistochemical comparison of gastrointestinal stromal tumor and solitary fibrous tumor. Arch Pathol Lab Med 2002;126(10):1189-92.
45
Yamaguchi U, Hasegawa T, Masuda T, Sekine · Akira Kawai S, Chuman H, et al.Differential diagnosis of gastrointestinal stromal tumor and other spindle cell tumors in the gastrointestinal tract based on immunohistochemical analysis. Virchows Arch 2004;445(2):142-150.
46
Cho KJ, Ro JY, Choi SH, Nam SY, Kim SY. Mesenchymal neoplasms of the major salivary glands:clinicopathological features of 18 cases. Eur Arch Otorhinolaryngol 2008;265 (Suppl 1) S47-S56.
47
O’regan EM, Vanguri V, Allen CM, Eversole LR, Wright JM, Woo SB. Solitary Fibrous Tumor of the Oral Cavity: Clinicopathologic and Immunohistochemical Study of 21 Cases. Head and Neck Pathol 2009;3(2):106-115.
48
Blandamura S, Alaggio R, Bettini G, Guzzardo V, Valentini E, Bedogin A. Four cases of solitary fibrous tumour of the eye and orbit: one with sarcomatous transformation after radiotherapy and one in a 5-year-old child’s eyelid. J Clin Pathol 2014;67(3):263-67.
49
Mosquera JM, Fletcher CD. Expanding the Spectrum of Malignant Progression in Solitary Fibrous Tumors. A Study of 8 Cases With a Discrete Anaplastic Component— Is This Dedifferentiated SFT? Am J Surg Pathol 2009;33(9): 1314-1321.
50
Demicco EG, Park MS, Araujo DM, Fox PS, Bassetts RL, Pollock RE, et al.Solitary fibrous tumor: a clinicopathological study of 110 cases and proposed risk assessment model. Mod Pathol 2012;25 (9): 1298-1306.
51
Subramaniam MM, Lim XY, Venkateswaran K, Shuen CS, Soong R, Petersson F. Dedifferentiated solitary fibrous tumour of the nasal cavity: the first case reported with molecular characterization of a TP53 mutation. Histopathology 2011;59(6):1269-79.
52
Collini P, Negri T, Barisella M, Palassini E, Tarantino E, Pastorino U, et al. High-grade Sarcomatous Overgrowth in Solitary Fibrous Tumors.A Clinicopathologic Study of 10 Cases. Am J Surg Pathol 2012;36 (8):1202-1215.
53
ORIGINAL_ARTICLE
Evaluation of Aryoseven Safety (Recombinant Activated Factor VII) in Patients with Bleeding Disorders (An Observational Post-Marketing Surveillance Study)
Background: Recombinant activated factor VII induces hemostasis in patients with coagulopathy disorders. AryoSeven™ as a safe Iranian Recombinant activated factor VII has been available on our market. This study was performed to establish the safety of AryoSeven on patients with coagulopathy disorder. Methods: This single-center, descriptive, cross sectional study was carried out in Thrombus and Homeostasis Research Center ValiAsr Hospital during 2013-2014. Fifty one patients with bleeding disorders who received at least one dose of Aryoseven were enrolled. Patients’ demographic data and adverse effect of drug and reaction related to Aryoseven or previous usage of Recombinant activated FVII were recorded in questionnaires. Finally data were analyzed to compare side effects of Aryoseven and other Recombinant activated FVII brands. Results: Aryoseven was prescribed for 51 Patients. Of all participants with mean age 57.18+21.38 yr, 31 cases were male and 26 subjects had past history of recombinant activated FVII usage. Glanzman was the most frequent disorder followed by congenital FVII deficiency, hemophilia with inhibitors, factor 5 deficiency, acquired hemophilia, hemophilia A with inhibitor, and hemophilia A or B with inhibitor. The majority of bleeding episodes had occurred in joints. Three patients (5.9%) complained about adverse effects of Aryoseven vs. 11.5 % about adverse effects of other brands. However this difference was not significant, statistically. Conclusion: Based on monitor patients closely for any adverse events, we concluded that Aryoseven administration under careful weighing of benefit versus potential harm may comparable with other counterpart drugs. How to cite this article: Toogeh G, Abolghasemi H, Eshghi P, Managhchi M, Shaverdi-niasari M, Karimi K, et al. Evaluation of Aryoseven Safety (recombinant activated factor VII) in patients with bleeding disorders (An observational post-marketing surveillance, study). Iran J Pathol. 2016; 11(3):204-9.
https://ijp.iranpath.org/article_19724_650ceeba52c0fc85a0817836cb94a1ba.pdf
2016-07-01
204
209
Aryoseven
Safety
bleeding disorders
Gholamreza
Toogeh
gh.tooge@yahoo.com
1
Thromboses Hemostasis Research Center, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Hassan
Abolghasemi
2
Pediatric Congenital Hematologic Disorders Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
AUTHOR
Peyman
Eshghi
peyman64@yahoo.com
3
Pediatric Congenital Hematologic Disorders Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
AUTHOR
Mohammadreza
Managhchi
4
Thromboses Hemostasis Research Center, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Mohammadreza
Shaverdi-niasari
5
Thromboses Hemostasis Research Center, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Katayoon
Karimi
6
Thromboses Hemostasis Research Center, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Samin
Roostaei
7
Thromboses Hemostasis Research Center, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Neda
Emran
8
Thromboses Hemostasis Research Center, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Alireza
Abdollahi
dr_p_abdollahi@yahoo.com
9
Thromboses Hemostasis Research Center, Tehran University of Medical Sciences, Tehran, Iran
LEAD_AUTHOR
Hedner U, Ingerslev J. Clinical Use of Recombinant FVIIa (rFVIIa). Transfus Sci 1998; 19 (2): 163-76.
1
Chi-Cheng Li, Ji-Hung Wang, Yen-Ta Huang, Han-Yu Huang, Tso-Fu Wang,Sung-Chao Chu,etal. Clinical Experiences with Recombinant Activated FactorVII for Managing Uncontrolled Hemorrhage in Non-Hemophilic Patients. Tzu Chi Med J 2007 ; 19 ( 4) :220–5.
2
YakovYusim, AzrielPerel, HaimBerkenstadt , Moshe Attia , NachshonKnollerMDb, AvnerSidi. The use of recombinant factor VIIa (NovoSeven) for treatment of active or impending bleeding in brain injury: broadening the indications. J Clin Anesthesia 2006; 18: 545–51.
3
Man-Chiu Poon. The Evidence for the Use of Recombinant Human ActivatedFactor VII in the Treatment of Bleeding Patients WithQuantitative and Qualitative Platelet Disorders. Transfusion Med Rev 2007; 21(3): 223-36.
4
Ulla Hedner. Recombinant Factor VIIa (NovoSeven) as a Hemostatic Agent. Dis Mon 2003; 49:39-48.
5
Geffen M, Mathijssen N, Holme P, Laros-van Gorkom B, van KraaijM.Masereeuw R, et al. Pharmacodynamics of recombinant activated factor VII and plasma-derivedfactor VII in a cohort of severe FVII deficient patients. Thrombosis Res 2013;132:116–22.
6
Hemophilia Management. The United States Pharmacopeial Convention, Inc. Transfusion Med Rev, 1998; 12(2): 128-140.
7
Skinner M, Mannucci PM, Farrugia A, DiMichele D, Bolton-Maggs P. et al. Global Forum of the World Federation of Hemophilia, 2005, Montreal, Quebec, Canada. Transfusion Apheresis Sci2006; 35:151–72.
8
Eshghi P, Mahdavi-Mazdeh M, Karimi, M, Aghighi M. Haemophilia in the developing countries: the Iranian experience. Arch Med Sci 2010; 6(1): 83–9.
9
Abshire T, Kenet G. Safety updates on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors. Haemophilia 2008; 14(5):898-902.
10
BirschmannI, KlamothR, Eichler H, Schenk J, KirchamaierC M, HalimehS. Results of the WIRK prospective, non-interventional observational study of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disorders. Haemophilia 2013; 19, 679–85.
11
Fischer K, Pouw ME, Lewandowski D, Janssen MP, van den Berg HM, van Hout BA. A modeling approach to evaluate long-term outcome of prophylactic and on demand treatment strategies for severe hemophilia A. Haematologica 2011; 96: 738–43.
12
Ehrenforth S, Kreuz W, Scharrer I et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594–8.
13
Darby SC, Keeling DM, Spooner RJ et al. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977–99. J Thromb Haemost 2004; 2: 1047–54.
14
Bain J, Lewis D, Bernard A, Hatton K, Reda H, Flynn J. Implementation of an off-label recombinant factor VIIa protocol for patients with critical bleeding at an academic medical center. J Thromb Thrombolysis. 2014 Nov;38(4):447-52.
15
Salaj P, Brabec P, Penka M, Pohlreichova V, Smejkal P, CetkovskyP,etalEffect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic. Haemophilia 2009; 15: 752–9.
16
Young G, Cooper DL, Gut RZ. Dosing and effectiveness of recombinant activated factor VII (rFVIIA) in congenital haemophilia with inhibitors by bleed type and location: the experience of the Haemophilia and Thrombosis Research Society (HTRS) Registry (2004–2008). Haemophilia 2012;18(6):990-6.
17
Young G, Shapiro AD, Walsh CE, Gruppo RA, Gut RZ, Cooper DL. Patient/caregiverreported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE). Haemophilia 2012; 18: 392–9.
18
Key NS, Aledort LM, Beardsley D, Cooper HA, Davignon G, Ewenstein BM, et al.Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912–8.
19
Parameswaran R, Shapiro AD, Gill JC, Kessler CM. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 2005; 11: 100–6.
20
Salaj P, Ovesna P, Penka M, Hedner U. Analyses of recombinant activated factor VII treatments from clinical practice for rapid bleeding and acute pain control in haemophilia patients with inhibitors. Haemophilia 2012; 18: 409–11.
21
ORIGINAL_ARTICLE
BK Viremia among Iranian Renal Transplant Candidates
Background: Primary infection with BK virus (BKV) is occurred during childhood and usually asymptomatic, but after initial infection, BKV may persist lifelong in the kidney and genitourinary tract. Reactivation may occur in individuals with compromised immunity such as renal transplant recipients. Due to the role of BKV in BK virus-associated nephropathy (BKVAN) and potentially renal allograft rejection, the detection of BKV in renal transplant candidates is very important. The aim of this study was to evaluate the frequency of BK viremia in end stage renal disease cases who were candidates for renal transplantation. Methods: In this cross-sectional study, 50 cases with end stage renal disease who were candidates for renal transplantation were recruited from the main dialysis unit in Tehran, Iran. Presence of BK viremia was determined in plasma samples of cases using real time PCR. Results: A total of 50 renal transplant candidates with mean age 37.8±13 yr were enrolled in the study. Fifty two percent of subjects were male. Forty six (92%) of them were under HD and 4 (8%) were on PD. BK virus was not detected in any plasma samples of renal transplant candidates. Conclusion: This study showed absence of BK viremia in our renal transplant candidates. However, due to the important role of BKV in BKVAN and renal graft failure and rejection, further studies involving larger number of cases are required to elucidate the rate of the BKV in renal transplant candidates.
How to cite this article:
Jozpanahi M, Ramezani A, Ossareh S, Banifazl M, Bavand A, Mamishi S, et al. BK Viremia among Iranian Renal Transplant Candidates. Iran J Pathol. 2016; 11(3):210-5.
https://ijp.iranpath.org/article_19725_c6c8fe241477d519e1c3eab6d8aae293.pdf
2016-07-01
210
215
BK virus (BKV)
Prevalence
Renal transplant candidates
Manizheh
Jozpanahi
dr.panahi48@gmail.com
1
Zanjan University of Medical Sciences, Zanjan, Iran
AUTHOR
Amitis
Ramezani
amitisramezani@hotmail.com
2
Clinical Research Dept., Pasteur Institute of Iran, Tehran, Iran
AUTHOR
Shahrzad
Ossareh
ossareh_s@hotmail.com
3
Hasheminejad Kidney Center, Iran University of Medical Science, Tehran, Iran
AUTHOR
Mohammad
Banifazl
mohammadbanifazl@aol.com
4
Iranian Society for Support of Patients with Infectious Diseases, Tehran, Iran
AUTHOR
Anahita
Bavand
anahita_bvd@yahoo.com
5
Clinical Research Dept., Pasteur Institute of Iran
AUTHOR
Setareh
Mamishi
smamishi@gmail.com
6
Pediatric Infectious Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Arezoo
Aghakhani
araghakhani@hotmail.com
7
Clinical Research Dept., Pasteur Institute of Iran, Tehran, Iran
LEAD_AUTHOR
Hirsch HH, Steiger J. Polyomavirus BK. Lancet Infect Dis 2003; 3(10):611-23.
1
Barraclough KA, Isbel NM, Staatz CE, Johnson DW.BK Virus in Kidney Transplant Recipients:The Influence of Immunosuppression. J Transplant 2011; 2011:750836
2
Garces JC. BK Virus-Associated Nephropathy in Kidney Transplant Recipients. Ochsner J 2010; 10(4):245-9.
3
Dalianis T, Hirsch HH. Human polyomaviruses in disease and cancer. Virology 2013; 437:63e72.
4
Knowles WA.Propagation and assay of BK virus. Methods Mol Biol 2001; 165:19-31.
5
Costa C, Bergallo M, Sidoti F, Astegiano S, Terlizzi ME, Mazzucco G, et al. Polyomaviruses BK And JC DNA quantitation in kidney allograft biopsies. J Clin Virol 2009; 44:20–23.
6
Randhawa P, Ramos E. BK viral nephropathy: an overview. Transplant Rev 2007; 21:77-85.
7
Bohl DL, Brennan DC. BK virus nephropathy and kidney transplantation, Clin J Am Soc Nephrol 2007; 2(supp1): S36-S46.
8
Arthur RR, Dagostin S, Shah KV. Detection of BK virus and JC virus in urine and brain tissue by polymerase chain reaction. J Clin Microbiol 1989; 27 (6): 1174-1179.
9
Akhgari S, Mohraz M, Azadmanesh K, Vahabpour R, Kazemimanesh M, Aghakhani A, et al. Frequency and subtype of BK virus infection in Iranian patients infected with HIV. Med Microbiol Immunol 2015 Jul 4. [Epub ahead of print]
10
Hirsch HH, Brennan DC, Drachenberg CB, Ginevri F, Gordon J, Limaye AP, et al.Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation 2005; 79(10):1277-86.
11
Sharif A, Sharif MR, Aghakhani A, Banifazl M, Hamkar R, Ghavami N, et al. Prevalence of BK viremia in Iranian hemodialysis and peritoneal dialysis patients. Infect Dis (Lond) 2015;47(5):345-8.
12
Soleymanian T, Rasulzadegan MH, Sotoodeh M, Ganji MR, Naderi G, Amin M, et al. Low prevalence of BK virus nephropathy on nonprotocol renal biopsies in Iranian kidney transplant recipients: one center's experience and review of the literature. Exp Clin Transplant 2010; 8(4):297-302.
13
Soleymanian T, Keyvani H, Jazayeri SM, Fazeli Z, Ghamari S, Mahabadi M, et al. Prospective study of BK virus infection and nephropathy during the first year after kidney transplantation. Iran J Kidney Dis 2014; 8(2):145-51.
14
Nasiri S, Ahmadi SF, Lessan-Pezeshki M, Seyfi S, Alatab S. Lack of cytomegalovirus and polyomavirus coexistence in Iranian kidney transplant recipients. Transplant Proc 2011; 43(2):536-9
15
Alangaden GJ, Thyagarajan R, Gruber SA, Morawski K, Garnick J, El-Amm JM, et al. Infectious complications after kidney transplantation: current epidemiology and associated risk factors. Curr Transplant 2006; 20:401e9.
16
Sousa SR, Galante NZ, Barbosa DA, Pestana JM. Incidence of infectious complications and their risk factors in the first year after renal transplantation. J Bras Nefrol 2010; 32:75e82.
17
Pourmand G, Salem S, Mehrsai A, Taherimahmoudi M, Ebrahimi R, Pourmand MR. Infectious complications after kidney transplantation: a single center experience. Transpl Infect Dis 2007; 9:302e9.
18
Lipshutz GS, Flechner SM, Govani MV, Vincenti F. BK nephropathy in kidney transplant recipients treated with a CNI-free immunosuppression regimen. Am J Transplant 2004; 4:2132–4.
19
Pakfetrat M, Yaghobi R, Salmanpoor Z, Roozbeh J, Torabinezhad S, Kadkhodaei S. Frequency of Polyomavirus BK Infection in Kidney Transplant Patients Suspected to Nephropathy. Int J Organ Transplant Med 2015; 6(2):77-84.
20
Alméras C, Foulongne V, Garrigue V, Szwarc I, Vetromile F, Segondy M, et al. Does reduction in immunosuppression in viremic patients prevent BK virus nephropathy in de novo renal transplant recipients? A prospective study. Transplantation 2008; 85:1099–104.
21
Ginevri F, Azzi A, Hirsch HH, Basso S, Fontana I, Cioni M, et al. Prospective monitoring of polyomavirus BK replication and impact of pre-emptive intervention in pediatric kidney recipients. Am J Transplant 2007; 7:2727-35.
22
Taheri S, Kafilzadeh F, Shafa M, Yaran M, Mortazavi M, Seirafian S, et al. Comparison of polyomavirus (BK virus and JC viruses) viruria in renal transplant recipients with and without kidney dysfunction. J Res Med Sci 2011; 16:916-22.
23
Boudreault AA, Courtemanche C, Latulippe E, Côté I, Houde I, Deschênes L. Screening for polyomavirus associated nephropathy in renal transplantation with blood viral load measurement. J Clin Virol 2009; 45:318-21.
24
Kaydani GA, Makvandi M, Samarbafzadeh A, Shahbazian H, Hamidi Fard M. Prevalence and Distribution of BK virus Subtypes in Renal Transplant Recipients Referred to Golestan Hospital in Ahvaz, Iran. Jundishapur J Microbiol 2015; 8(3):e16738.
25
Bofill-Mas S, Clemente-Casares P, Major EO, Curfman B, Girones R. Analysis of the excreted JC virus strain and their potential oral transmission. J Neurovirol 2003; 9:498–507.
26
Bofill-Mas S, Girones R. Excretion and transmission of JCV in human populations. J Neurovirol 2001;7:345–349.
27
Mitterhofer AP, Tinti F, Pietropaolo V, Umbro I, Anzivino E, Bellizzi A, et al. Role of BK virus infection in end-stage renal disease patients waiting for kidney transplantation--viral replication dynamics from pre- to post-transplant. Clin Transplant 2014; 28(3):299-306.
28
Miller S, Liverman CS, Post L, Khan Y, Wright C. Analytical and clinical performance characteristics of the Sim- plexa BK virus quantitative PCR assay for the diag- nosis of polyomavirus-associated nephropathy in renal transplant recipients using plasma and urine specimens. J Clin Virol 2012; 55:310-16.
29
Naumnik B, Kowalewska J, Zalewski G, Charkiewicz R, Myśliwiec M. The status of BK polyomavirus replication in adult renal transplant recipients in northeastern Poland. Transplant Proc 2011; 43(8):2976-84.
30
Boobes Y, Bernieh B, Hussain Q, Al Omary H, Al Hakim MR, Abayechi F, et al. Prevalence of polyomavirus among United arab emirates kidney transplant recipients: results from a single center. Transplant Proc 2015; 47(4):1143-5.
31
Boukoum H, Nahdi I, Sahtout W, Skiri H, Aloui S, Achour A, et al.BK and JC polyomavirus infections in Tunisian renal transplant recipients. J Med Virol 2015 May 7. doi: 10.1002/jmv.24234. [Epub ahead of print]
32
Melo FA, Bezerra AC, Santana BB, Ishak MO, Ishak R, Cayres-Vallinoto IM, et al. JC polyomavirus infection in candidates for kidney transplantation living in the Brazilian Amazon region. Mem Inst Oswaldo Cruz 2013; 108(2):145-9.
33
ORIGINAL_ARTICLE
Polymorphism of IL-28B Gene (rs12979860) in HCV Genotype 1 Patients Treated by Pegylated Interferon and Ribavirin
Background: Nowadays, the immune response to hepatitis C (HCV) treatment has become a crucial issue mostly due to the interleukin 28B (IL-28B) polymorphism effects in chronic HCV patients. The aim of this study was to detect the polymorphism of IL-28B gene (rs12979860) in HCV genotype 1 patients treated with pegylated Interferon and Ribavirin. Methods: From the 2010 to 2012, a total of 115 peripheral blood mononuclear cells (PBMCs) of HCV patients who presented to Gastrointestinal & Liver Disease Research Center (GILDRC), Firoozgar Hospital, Tehran, Iran were enrolled in this retrospective cross sectional study. Samples were then categorized based on the presence of sustained virologic response (SVR and no-SVR). Variables including age, gender, serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels of the two groups were investigated based on different IL-28B genotypes. Results: Analysis by the variables of age and gender showed a mean age ± SD of 42.1±14.0 and gender variability of 44 females (38.2%) and 71 males (61.8%). Adding up these results, the analysis of ALT levels revealed that there was between 293 and 14 mg/ml; AST levels ranged between 217 and 17 mg/ml; the viral load (HCV RNA) ranged between 7,822,000 and 50 IU/ml; the prevalence of CC, CT and TT genotypes were 90.9%, 54% and 25.0%. Conclusion: IL-28B polymorphism has an effective impact on the therapeutic response to ribavirin and peginterferon combination therapy in chronic HCV patients infected by different genotypes. This polymorphism is crucial in natural clearance.
How to cite this article:
Safarnezhad Tameshkel F, Karbalaie Niya MH, Sohrabi M, Panahi M, Zamani F, Imanzade F, et al. Polymorphism of IL-28B Gene (rs12979860) in HCV Genotype 1 Patients Treated by Pegylated Interferon and Ribavirin. Iran J Pathol. 2016; 11(3):216-21.
https://ijp.iranpath.org/article_19286_99660f0ba19c08b902097f75a22fd76a.pdf
2016-07-01
216
221
Chronic HCV infection
Sustained virologic response
Interleukin 28B polymorphism
Fahimeh
Safarnezhad Tameshkel
fahime.1615@yahoo.com
1
Gastrointestinal & Liver Disease Research Center (GILDRC), Iran University of Medical Sciences, Tehran, Iran
AUTHOR
Mohmmad Hadi
Karbalaie Niya
karbalai.m2011@gmail.com
2
Dept. of Virology, Iran University of Medical Sciences, Tehran, Iran
AUTHOR
Masuodreza
Sohrabi
sohrab_r@yahoo.com
3
Gastrointestinal & Liver Disease Research Center (GILDRC), Iran University of Medical Sciences, Tehran, Iran
AUTHOR
Mahshid
Panahi
mahshid.panahi@yahoo.com
4
Gastrointestinal & Liver Disease Research Center (GILDRC), Iran University of Medical Sciences, Tehran, Iran
AUTHOR
Farhad
Zamani
zamani.farhad@gmail.com
5
Gastrointestinal & Liver Disease Research Center (GILDRC), Iran University of Medical Sciences, Tehran, Iran
AUTHOR
Farid
Imanzade
n_rakhshani@yahoo.com
6
Dept. of Pediatrics, Shahid Beheshti University of Medical Sciences, Tehran, Iran
AUTHOR
Nasser
Rakhshani
mohamad.karbalai@yahoo.com
7
Gastrointestinal & Liver Disease Research Center (GILDRC), Iran University of Medical Sciences, Tehran, Iran
LEAD_AUTHOR
Afzal MS, Ahmed T, Zaidi NU. Comparison of HCV prevalence in pakistan and iran; an insight into future. Hepat Mon 2014;14(1):e11466.
1
Jahanbakhsh Sefidi F, Keyvani H, Monavari SH, Alavian SM, Fakhim S, Bokharaei-Salim F. Distribution of hepatitis C virus genotypes in Iranian chronic infected patients. Hepat Mon 2013;13(1):e7991.
2
Asselah T, Marcellin P. Optimal IFN-free therapy in treatment-naive patients with HCV genotype 1 infection. Liver Int 2015;35 Suppl 1:56-64.
3
Sekkides O. Assessing a broader user base for new HCV drug. Lancet Infect Dis 2015;15(4):383.
4
Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010;139(3):821-7, 7 e1.
5
Obach D, Yazdanpanah Y, Esmat G, Avihingsanon A, Dewedar S, Durier N, et al. How to optimize hepatitis C virus treatment impact on life years saved in resource-constrained countries. Hepatology 2015;62(1):31-9.
6
Lange CM, Zeuzem S. IL28B single nucleotide polymorphisms in the treatment of hepatitis C. J Hepatol 2011;55(3):692-701.
7
Bruno S, Thompson AJ, Critelli R, Crosignani A, Rossi S, De Lisi S, et al. Interferon lambda-3 is not associated with clinical outcome in patients with HCV-induced compensated cirrhosis: a long-term cohort study. Antiviral Res 2015;113:27-32.
8
Mahboobi N, Behnava B, Alavian SM. IL28B SNP genotyping among Iranian HCV-infected patients: A preliminary report. Hepat Mon 2011;11(5):386-8.
9
Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009;41(10):1100-4.
10
Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41(10):1105-9.
11
Aziz H, Raza A, Ali K, Khattak JZ, Irfan J, Gill ML. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy. Int J Infect Dis 2015;30:91-7.
12
Taheri S AB, Korkmaz K, Yildiz O, Zararsiz G, Canatan H. Characterization of the interleukin-28B gene rs12979860 C/T polymorphism in Turkish chronic hepatitis C patients and healthy individuals. Balkan Med J 2015(32):147-55.
13
Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD, et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010;52(6):1888-96.
14
Berger CT, Kim AY. IL28B polymorphisms as a pretreatment predictor of response to HCV treatment. Infect Dis Clin North Am 2012;26(4):863-77.
15
El-Awady MK, Mostafa L, Tabll AA, Abdelhafez TH, Bader El Din NG, Zayed N, et al. Association of IL28B SNP With Progression of Egyptian HCV Genotype 4 Patients to End Stage Liver Disease. Hepat Mon 2012;12(4):271-7.
16
Liao XW, Ling Y, Li XH, Han Y, Zhang SY, Gu LL, et al. Association of genetic variation in IL28B with hepatitis C treatment-induced viral clearance in the Chinese Han population. Antivir Ther 2011;16(2):141-7.
17
ORIGINAL_ARTICLE
Designing and Development of a DNA Vaccine Based On Structural Proteins of Hepatitis C Virus
Background: Hepatitis C virus (HCV) infection is one of the most prevalent infectious diseases responsible for high morbidity and mortality worldwide. Therefore, designing new and effective therapeutics is of great importance. The aim of the current study was to construct a DNA vaccine containing structural proteins of HCV and evaluation of its expression in a eukaryotic system. Methods: Structural proteins of HCV (core, E1, and E2) were isolated and amplified from JFH strain of HCV genotype 2a using PCR method. The PCR products were cloned into pCDNA3.1 (+) vector and finally were confirmed by restriction enzyme analysis and sequencing. The eukaryotic expression of the vector was confirmed by RT-PCR. Results: Recombinant vector containing 2241bp fragment of HCV structural genes was constructed.The desired plasmid was sequenced and corresponded to 100% identity with the submitted sequences in GenBank. RT-PCR results indicated that the recombinant plasmid could be expressed efficiently in the eukaryotic expression system. Conclusion: Successful cloning of structural viral genes in pCDNA3.1 (+) vector and their expression in a eukaryotic expression system facilitates the development of new DNA vaccines against HCV. A DNA vaccine encoding core-E1-E2 antigens was designed. The desired expression vector can be used for further attempts in the development of vaccines.
https://ijp.iranpath.org/article_19287_5449388f49745a817746877a385b272e.pdf
2016-07-01
222
230
HCV
Structural proteins
DNA Vaccine
Roghayeh
Teimourpour
r.teymourpour@gmail.com
1
Antimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Amineh Sadat
Tajani
tajania891@mums.ac.ir
2
Pharmacy School, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Vahid Reza
Askari
askariv891@mums.ac.ir
3
Pharmacy School, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Sina
Rostami
sina.rostami@student.uib.no
4
The Influenza Centre, Department of Clinical Science, University of Bergen, N-5021 Bergen, Norway
AUTHOR
Zahra
Meshkat
meshkatz@mums.ac.ir
5
Antimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
LEAD_AUTHOR
ORIGINAL_ARTICLE
Expression of Vascular Endothelial Growth Factor in Nasal Polyp and Chronic Rhinosinusitis
Background: Nasal inflammatory disorders such as chronic rhinosinusitis and nasal polyp are among the most prevalent complications with high socioeconomic costs. Vascular Endothelial Growth Factor (VEGF) plays a key role in angiogenesis and cell proliferation. In the present study the effect of VEGF on the development and prognosis of chronic rhinosinusitis and nasal polyp was investigated. Methods: This cross sectional study was performed on the nasal histological specimens of two groups of patients suffering from nasal polyp or chronic rhinosinusitis, and the expression of VEGF in the two groups was compared immunohistochemically. Based on the percentage of VEGF-positive cells the specimens were classified into four scores. Furthermore, the relations between the VEGF expression and some demographic characteristics were evaluated. Results: The VEGF immunohistochemistry findings indicated a significantly higher expression of VEGF in nasal polyp group compared to chronic rhinosinusitis without nasal polyp group. In terms of VEGF-expression scoring, in both groups most of the specimens were classified as score-2, namely indicating 10-50% of VEGF-positive epithelial cells. In both groups no significant relation between VEGF expression and age or sex of the patients could be seen. Conclusion: Local modulation of VEGF expression might be taken as a putative therapeutic strategy in management of sinunasal inflammatory disorders, especially nasal polyps.
https://ijp.iranpath.org/article_19726_df713ddb7727bfd7d7f7ef12f4f37feb.pdf
2016-07-01
231
237
VEGF
Nasal polyp
Chronic rhinosinusitis
Alireza
Azizzadeh Delshad
delshada@yahoo.com
1
Dept. of Anatomical Sciences and Pathology, Faculty of Medicine, Shahed University, Tehran, Iran
LEAD_AUTHOR
Mohammadreza
Jalali Nadoushan
jalalinadooshan@yahoo.com
2
Dept. of Anatomical Sciences and Pathology, Faculty of Medicine, Shahed University, Tehran, Iran
AUTHOR
Ali
Davati
davati@shahed.ac.ir
3
Dept. of Anatomical Sciences and Pathology, Faculty of Medicine, Shahed University, Tehran, Iran
AUTHOR
Aida
Rostami
aidarostami@gmail.com
4
Dept. of Anatomical Sciences and Pathology, Faculty of Medicine, Shahed University, Tehran, Iran
AUTHOR
Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, et al. EPOS: European position paper on rhinosinusitis and nasal polyps 2012 A summary for otorhinolaryngologists. Rhinology. 2012;50:1–12. [PubMed]
1
Kato A. Immunology of chronic rhinosinusitis. Alergology Int. 2015;64:121–30. [PMC free article] [PubMed]
2
Anselmo-Lima WT, Sakano E, Tamashiro E, Araujo E, Ortiz E, Pinna F. Rhinosinusitis: evidence and experience. Braz J Orthorhinolaryngol. 2015;81(Sup 1):S1–S49. [PubMed]
3
Cingi C, Demirbas D, Ural A. Nasal Polyposis: An Overview of Differential Diagnosis and Treatment. Recent Patents on Inflammation & Allergy Drug Discovery. 2011;5(3):241–252. [PubMed]
4
Dykewicz MS, Hamilos DL. Rhinitis and sinusitis. J Allergy Clin Immunol. 2010;125(2):S103–S110. [PubMed]
5
Akdis CA, Bacher C, Cingi C, Dykewicz MS, Hellings PW, Naclerio RM, et al. Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European academy of allergy and clinical immunology and the American academy of alergy, asthma and immunology. J Allergy Clin Immunol. 2013;131:1479–90. [PMC free article] [PubMed]
6
Van Bruaene N, Bacher C. Tissue remodeling in chronic rhinosinusitis. Curr Opin Allergy Clin Immunol. 2011;11:8–11. [PubMed]
7
Stjarne P, Blomgren K, Caye-Thomasen P, Salo S, Soderstrom T. The efficacy and safety of once-daily mometasone furoate nasal spray in nasal polyposis: a randomized, double-blind, placebo-controlled study. Acta Otolaryngol. 2006;126:606–12. [PubMed]
8
Wallwork B, Coman W, Mackay-Sim A, Greiff L, Cervin A. A double-blind, randomized, placebo-controlled trial of macrolide in the treatment of chronic rhinosinusitis. Laryngoscope. 2006;116:189–193. [PubMed]
9
Coste A, Brugel L, Maître B, Boussat S, Papon JF, Wingerstmann L, et al. Inflammatory cells as well as epithelial cells in nasal polyps express vascular endothelial growth factor. Eur Respir J. 2000;15(2):367–72. [PubMed]
10
Kaner RJ, Ladetto JV, Singh R, Fukuda N, Matthay MA, Crystal RG. Lung overexpression of the vascular endothelial growth factor gene induces pulmonary edema. Am J Respir Cell Mol Biol. 2000;22:657–64. [PubMed]
11
Thanigaimani GD, Dhanaram B, Vijayalakshmi S. Histological analysis of Nasal Polyps in A Tertiary Hospital. J Dent Med Sci. 2015;14(6):18–20.
12
Saikuniene J, Vaitkus S, Japertine LM, Ryskiene S. Association of chronic rhinosinusitis with nasal polyps and asthma: clinical and radiological features, allergy and inflammation markers. Medicine (Kaunas) 2008;44(4):257–65. [PubMed]
13
Li C, Shi L, Yan Y, Gordon BR, Gordon WM, Wang DY. Gene Expression Signatures: A New Approach to Understanding the Pathophysiology of Chronic Rhinosinusitis. Current Allergy and Asthma Reports. 2013;13(2):209–17. [PubMed]
14
Dietz de Loos DAE, Hopkins C, Fokkens WJ. Symptoms in Chronic Rhinosinusitis with and without Nasal Polyps. Laryngoscope. 2013;123:57–63. [PubMed]
15
Lee H, Kim J. Constitutive expression of vascular endothelial cell growth factor (VEGF) gene family ligand and receptors on human upper and lower airway epithelial cells. Int Forum Allergy Rhinol. 2014;4(1):8–14. [PubMed]
16
Hu KH, Lee FP, Cheng YJ, Huang HM. Vascular endothelial growth factor and children featuring nasal polyp. Int J Pediatr Otorhinolaryngol. 2007;71:23–8. [PubMed]
17
Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O’Shea KS, et al. Heterozygous embryonic lethality by targeted inactivation of the VEGF gene. Nature. 1996;380:439–442. [PubMed]
18
Senger DR, Galli SJ, Dvorak AM, Peruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219:983–5. [PubMed]
19
Connolly DT, Heuvelman DM, Nelson R, Olander JV, Eppley BL, Delfino JJ, et al. Tumor vesicular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest. 1989;84:1470–8. [PMC free article] [PubMed]
20
Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362:841–4. [PubMed]
21
Ho CL, Sheu LF, Li CY. Immunohistochemical expression of basic fibroblast growth factor, vascular endothelial growth factor and their receptors in stage IV Non-Hodgkin lymphoma. Appl Immunohistochem Mol Morphol. 2002;10:316–21. [PubMed]
22
Rahimi N. VEGFR-1 andVEGFR-2: two non-identical twins with aunique physiognomy. Front Biosci. 2006;11:818–29. [PMC free article] [PubMed]
23
Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH. Di!erent signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem. 1994;269:26988–95. [PubMed]
24
Fruth K, Zhu C, Schramek E, Angermair J, Kassem W, Haxel BR, et al. Vascular Endothelial Growth Factor Expression in Nasal Polyps of Aspirin-Intolerant Patients. Arch Otolaryngol Head Neck Surg. 2012;138(3):286–93. [PubMed]
25
ORIGINAL_ARTICLE
Species-specific PCR for the Diagnosis and Determination of Antibiotic Susceptibilities of Brucella Strains Isolated from Tehran, Iran
Background: Brucellosis is an endemic zoonotic disease in the Middle East. This study intended to design a uniplex PCR assay for the detection and differentiation of Brucella at the species level and determining the antibiotic susceptibility pattern of Brucella in Iran. Methods: Sixty-eight Brucella specimens (38 animal and 30 human specimens) were analyzed using PCR (using one pair of primers). Antibiotic susceptibility patterns were evaluated and compared using the E-Test and disk diffusion susceptibility test. Tigecycline susceptibility pattern was compared with other antibiotics. Results: Thirty six isolates of B. melitensis, 2 isolates of B. abortus and 1 isolate of B. suis from the 38 animal specimens, 24 isolates of B. melitensis and 6 isolates of B. abortus from the 30 human specimens were differentiated. The MIC50 values of doxycycline for human and animal specimens were 125 and 10 μg/ml, respectively, tigecycline 0.064 μg/ml for human specimens and 0.125μg/ml for animal specimens, and trimethoprim/ sulfamethoxazole and ciprofloxacin 0.065 and 0.125μg/ml, respectively, for both human and animal specimens. The highest MIC50 value of streptomycin in the human specimens was 0.5μg/ml and 1μg/ml for the animal specimens. The greatest resistance shown was to tetracycline and gentamicin, respectively. Conclusion: Uniplex PCR for the detection and differentiation of Brucella at the strain level is faster and less expensive than multiplex PCR, and the antibiotics doxycycline, rifampin, trimethoprim-sulfamethoxazole, ciprofloxacin, and ofloxacin are the most effective antibiotics for treating brucellosis. Resistance to tigecycline is increasing, and we recommend that it be used in a combination regimen.
https://ijp.iranpath.org/article_19727_23d4de1c48a70a48acaf0df248ee267c.pdf
2016-07-01
238
247
Uniplex PCR
Brucella
Antibiotic Susceptibilities
Tigecycline
Faramarz
Masjedian Jazi
fmasjedian@yahoo.com
1
Dept. of Microbiology, Iran University of Medical Sciences, Tehran. Iran
AUTHOR
Gholamreza
Irajian
dr.irajian@gmail.com
2
Dept. of Microbiology, Iran University of Medical Sciences, Tehran. Iran
LEAD_AUTHOR
Reza
Mirnejad
rmirnejad@bmsu.ac.ir
3
Molecular Biology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
AUTHOR
Vahhab
Piranfar
vahab.p@gmail.com
4
Molecular Biology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
AUTHOR
Taghi
zahraei salehi
tsalehi@ut.ac.ir
5
Dept. of Microbiology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.
AUTHOR
Noor
Amir Mozafari
amirmozafari@yahoo.com
6
Dept. of Microbiology, Iran University of Medical Sciences, Tehran. Iran
AUTHOR
Ehsanollah
Ghaznavi-rad
e.ghaznavirad@arakmu.ac.ir
7
Dept. of Microbiology and Immunology, Arak University of Medical Sciences, Arak, Iran
AUTHOR
Mahmoud
Khormali
mkhoramali@ut.ac.ir
8
Dept. of Microbiology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.
AUTHOR
Rubach MP, Halliday JE, Cleaveland S, Crump JA. Brucellosis in low-income and middle-income countries. Curr Opin Infect Dis 2013;26(5):404-12.
1
Parlak M, Guducuoglu H, Bayram Y, Cikman A, Aypak C, Kilic S, et al. Identification and determination of antibiotic susceptibilities of Brucella strains isolated from patients in van, Turkey by conventional and molecular methods. Int J Med Sci 2013;10(10):1406-11.
2
Russo G, Pasquali P, Nenova R, Alexandrov T, Ralchev S, Vullo V, et al. Reemergence of human and animal brucellosis, bulgaria. Emerg Infect Dis 2009;15(2):314-6.
3
Gwida M, Al Dahouk S, Melzer F, Rosler U, Neubauer H, Tomaso H. Brucellosis - regionally emerging zoonotic disease? Croat Med J 2010;51(4):289-95.
4
Sanodze L, Bautista CT, Garuchava N, Chubinidze S, Tsertsvadze E, Broladze M, et al. Expansion of brucellosis detection in the country of Georgia by screening household members of cases and neighboring community members. BMC Public Health 2015;15:459.
5
Alavi SM, Alavi L. Treatment of brucellosis: a systematic review of studies in recent twenty years. Caspian J Intern Med 2013;4(2):636-41.
6
Solera J. Treatment of human brucellosis. J Med Liban 2000;48(4):255-63.
7
Pappas G, Papadimitriou P, Christou L, Akritidis N. Future trends in human brucellosis treatment. Expert Opin Investig Drugs 2006;15(10):1141-9.
8
Joint FAO/WHO expert committee on brucellosis. World Health Organ Tech Rep Ser 1986;740:1-132.
9
Ersoy Y, Sonmez E, Tevfik MR, But AD. Comparison of three different combination therapies in the treatment of human brucellosis. Trop Doct 2005;35(4):210-2.
10
Solera J, Rodriguez-Zapata M, Geijo P, Largo J, Paulino J, Saez L, et al. Doxycycline-rifampin versus doxycycline-streptomycin in treatment of human brucellosis due to Brucella melitensis. The GECMEI Group. Grupo de Estudio de Castilla-la Mancha de Enfermedades Infecciosas. Antimicrob Agents Chemother 1995;39(9):2061-7.
11
Yousefi-Nooraie R, Mortaz-Hejri S, Mehrani M, Sadeghipour P. Antibiotics for treating human brucellosis. Cochrane Database Syst Rev 2012;10:CD007179.
12
Ariza J, Bosilkovski M, Cascio A, Colmenero JD, Corbel MJ, Falagas ME, et al. Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations. PLoS Med 2007;4(12):e317.
13
Pappas G, Solera J, Akritidis N, Tsianos E. New approaches to the antibiotic treatment of brucellosis. Int J Antimicrob Agents 2005;26(2):101-5.
14
Al-Mariri A, Safi M. The Antibacterial Activity of Selected Labiatae (Lamiaceae) Essential Oils against Brucella melitensis. Iran J Med Sci 2013;38(1):44-50.
15
Aliskan H, Can F, Demirbilek M, Colakoglu S, Kilic S, Arslan H. Determining in vitro synergistic activities of tigecycline with several other antibiotics against Brucella melitensis using checkerboard and time-kill assays. J Chemother 2009;21(1):24-30.
16
Alton GG, Jones LM, Pietz DE. Laboratory techniques in brucellosis. Monogr Ser World Health Organ 1975(55):1-163.
17
Mirnejad R, Doust RH, Kachuei R, Mortazavi SM, Khoobdel M, Ahamadi A. Simultaneous detection and differentiates of Brucella abortus and Brucella melitensis by combinatorial PCR. Asian Pac J Trop Med 2012;5(1):24-8.
18
Mirnejad R, Mohamadi M, Piranfar V, Mortazavi SM, Kachuei R. A duplex PCR for rapid and simultaneous detection of Brucella spp. in human blood samples. Asian Pac J Trop Med 2013;6(6):453-6.
19
Bayram Y, Korkoca H, Aypak C, Parlak M, Cikman A, Kilic S, et al. Antimicrobial susceptibilities of Brucella isolates from various clinical specimens. Int J Med Sci 2011;8(3):198-202.
20
Dean AS, Crump L, Greter H, Schelling E, Zinsstag J. Global burden of human brucellosis: a systematic review of disease frequency. PLoS Negl Trop Dis 2012;6(10):e1865.
21
Magwedere K, Hemberger MY, Hoffman LC, Dziva F. Zoonoses: a potential obstacle to the growing wildlife industry of Namibia. Infect Ecol Epidemiol 2012;2.
22
Yu WL, Nielsen K. Review of detection of Brucella spp. by polymerase chain reaction. Croat Med J 2010;51(4):306-13.
23
Mirnejad R, Mohammadi M, Majdi A, Taghizoghi N, Piranfar V. Molecular Typing of Brucella melitensisand, B. abortus From Human Blood Samples Using PCR-RFLP Method. Jundishapur J Microbiol 2013;6(6):e7197.
24
Safi M, Al-Mariri A. Efficacy evaluation of some antibiotics against syrian Brucella spp isolates, in vitro. Braz J Microbiol 2012;43(4):1269-73.
25
Bertrand A. [Antibiotic treatment of brucellosis]. Presse Med 1994;23(24):1128-31.
26
Herzberg M, Elberg SS, Meyer KF. Immunization against brucella infection. II. Effectiveness of a streptomycin-dependent strain of Brucella melitensis. J Bacteriol 1953;66(5):600-5.
27
Simon EM, Berman DT. Pathogenicity and immunogenicity of streptomycin-dependent mutants of Brucella. J Bacteriol 1962;83:1347-55.
28
Abdel-Maksoud M, House B, Wasfy M, Abdel-Rahman B, Pimentel G, Roushdy G, et al. In vitro antibiotic susceptibility testing of Brucella isolates from Egypt between 1999 and 2007 and evidence of probable rifampin resistance. Ann Clin Microbiol Antimicrob 2012;11:24.
29
Trujillano-Martin I, Garcia-Sanchez E, Martinez IM, Fresnadillo MJ, Garcia-Sanchez JE, Garcia-Rodriguez JA. In vitro activities of six new fluoroquinolones against Brucella melitensis. Antimicrob Agents Chemother 1999;43(1):194-5.
30
Roushan MR, Mohraz M, Janmohammadi N, Hajiahmadi M. Efficacy of cotrimoxazole and rifampin for 6 or 8 weeks of therapy in childhood brucellosis. Pediatr Infect Dis J 2006;25(6):544-5.
31
Hashemi SH, Gachkar L, Keramat F, Mamani M, Hajilooi M, Janbakhsh A, et al. Comparison of doxycycline-streptomycin, doxycycline-rifampin, and ofloxacin-rifampin in the treatment of brucellosis: a randomized clinical trial. Int J Infect Dis 2012;16(4):e247-51.
32
Dizbay M, Kilic S, Hizel K, Arman D. Tigecycline: its potential for treatment of brucellosis. Scand J Infect Dis 2007;39(5):432-4.
33
Kilic S, Dizbay M, Cabadak H. In vitro activity of tigecycline, tetracycline and fluoroquinolones against Brucella melitensis. J Chemother 2008;20(1):33-7.
34
ORIGINAL_ARTICLE
The Oral Pathology Related Articles Published in Iranian Journal of Pathology from 2006 to 2015
Background: There is a paucity of information about the oral pathology related articles published in a pathology journal. This study aimed to audit the oral pathology related articles published in Iranian Journal of Pathology (Iran J Pathol)from 2006 to 2015. Methods: Bibliometric analysis of issues of Iran J Pathol from 2006 to 2015 was performed using web-based search.The articles published were analyzed for type of article and individual topic of oral pathology. The articles published were also checked for authorship trends. Results: Out of the total 49 published articles related to oral pathology, case reports (21) and original articles (18) contributed the major share. The highest number of oral pathology related articles was published in 2011, 2014 and 2015 with 8 articles each and the least published year was 2012 with 1 article. Among the oral pathology related articles published, spindle cell neoplasms (7) followed by salivary gland tumors (5), jaw tumors (4), oral granulomatous conditions (4), lymphomas (4), oral cancer (3) and odontogenic cysts (3) form the major attraction of the contributors. The largest numbers of published articles related to oral pathology were received from Tehran University of Medical Sciences; Tehran (7) followed by Mashhad University of Medical Sciences, Mashhad (6) and Shahid Beheshti University of Medical Sciences, Tehran (5). Conclusion: This paper may be considered as a baseline study for the bibliometric information regarding oral pathology related articles published in a pathology journal.
https://ijp.iranpath.org/article_19728_e8dfcb88ee4f0d823adc4b125b9253fc.pdf
2016-07-01
248
254
Oral Pathology
Iranian Journal of Pathology
Bibliometric analysis
Pathology Journal
Thorakkal
Shamim
shamu3duad@gmail.com
1
Dept. of Dentistry, Oral Pathology and Microbiology, Government Taluk Head Quarters Hospital, Malappuram, India
LEAD_AUTHOR
Shamim T. Forensic odontology. J Coll Physicians Surg Pak 2012; 22:240-5.
1
Shamim T. The relationship of forensic odontology with various dental specialties in the articles published in the Journal of Forensic odonto-stomatology from 2005 to 2012. Indian J Dent 2015; 6:75-80.
2
Shamim T. Publication trends in the journal of forensic dental sciences 2009-2012. J Sci Res 2013; 2:152-6.
3
Shamim T. The dental specialties related articles published in Medical Journal Armed Forces India from 2000 to 2014 over a 15-year period. Med J Armed Forces India 2015; 71:S400-10.
4
ORIGINAL_ARTICLE
Demsoplastic Small Round Cell Tumor:a Diagnostic and Therapeutic Dilemma
Desmoplastic small round cell tumor (DSCRT) is a rare variant of sarcoma with a highly aggressive behavior. It usually affects abdominal cavity and has a male predominance. Its correct diagnosis and treatment is sophisticated and requires an experienced multidisciplinary team. Hereby we present a 25 yrold man from Kerman Province in 2013 with abdominal mass and ascites who underwent sonograghy guided percutaneous needle biopsy which was misleading and inconclusive for diagnosis. Thus an open biopsy was fulfilled which revealed solid nests of small round cells with hyperchromatic nuclei and clear cytoplasm surrounded by a desmoplastic stroma suggestive for DSCRT. The diagnosis was confirmed by positive immunohitochemical reaction for cytokeratin, desmin and neuron specific enolase(NSE).Ultimately the patient underwent chemotherapy on the basis of P6 protocol without surgical debulking.Diagnosis and treatment of DSCRT could be a dilemma due to its rarity, various clinicopathologic mimickers and lack of a consensus about its management.
https://ijp.iranpath.org/article_19729_6f1cd2bfb36032bdbd2af5ce52a2d8d4.pdf
2016-07-01
255
260
Desmoplastic small round cell tumor
pathology
chemotherapy
needle biopsy
Moeinadin
Safavi
moein.safavi@gmail.com
1
Dept. of Pathology, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran
LEAD_AUTHOR
Jahanbanoo
Shahryari
jshahryari@yahoo.cam
2
Dept. of Pathology, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Mohammadmehdi
Moeini Aghtaei
moini_m@yahoo.com
3
Dept. of Pathology, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Hossein
Nikpour
hakimlab@yahoo.com
4
Dept. of Pathology, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Shen X-Z, Zhao J-G, Wu J-J, Liu F. Clinical and computed tomography features of adult abdominopelvic desmoplastic small round cell tumor. World J Gastroenterol 2014;20(17):5157-64.
1
Bellah R, Suzuki-Bordalo L, Brecher E, Ginsberg JP, Maris J, Pawel BR. Desmoplastic small round cell tumor in the abdomen and pelvis: report of CT findings in 11 affected children and young adults. Am J Roentgenol 2005;184(6):1910-4.
2
Kis B, O'Regan K, Agoston A, Javery O, Jagannathan J, Ramaiya N. Imaging of desmoplastic small round cell tumour in adults. Imaging 2012;85:185-92.
3
4 Heikkila A J, Prebtani A P. Desmoplastic small round cell tumour in a 74 year old man: an uncommon cause of ascites. Diagn Pathol 2011; 6, 55.
4
Hayes-Jordan A, Anderson PM. The diagnosis and management of desmoplastic small round cell tumor: a review. Curr Opin Oncol 2011;23(4):385-9.
5
Gerald WL, Rosai J, Ladanyi M. Characterization of the genomic breakpoint and chimeric transcripts in the EWS-WT1 gene fusion of desmoplastic small round cell tumor. Proc Natl Acad Sci 1995;92(4):1028-32.
6
Hafida B, Leila C, Abdelmalek O, Ouadii M, Siham T, Afaf Riffi A, et al. Desmoplastic small round cell tumor of the abdomen: A case report and literature review of therapeutic options. Health 2012;4(4)207-11.
7
Lae ME, Roche PC, Jin L, Lloyd RV, Nascimento AG. Desmoplastic small round cell tumor: a clinicopathologic, immunohistochemical, and molecular study of 32 tumors. Am J Surg Pathol 2002;26(7):823-35.
8
Zhang WD, Li CX, Liu QY, Hu YY, Cao Y, Huang JH. CT, MRI, and FDG-PET/CT imaging findings of abdominopelvic desmoplastic small round cell tumors: correlation with histopathologic findings. Eur J Radiol 2011 Nov;80(2):269-73.
9
Dufresne A, Cassier P, Couraud L, Marec-Bérard P, Meeus P, Alberti L, et al. Desmoplastic small round cell tumor: current management and recent findings. Sarcoma 2012;714986:2012.
10
Chang F. Desmoplastic small round cell tumors: cytologic, histologic, and immunohistochemical features. Arch Pathol Lab Med 2006;130(5):728-32.
11
Thandassery RB, Elbedawi M, El-Malik H, John AK, Al-Bozom IA, Al Kaabi SR. Intra-abdominal desmoplastic small round cell tumor. Ann Gastroenterol.2013; 27(3), 287-288.
12
Quaglia MPL, Brennan MF. The clinical approach to desmoplastic small round cell tumor. Surg Oncol 2000;9(2):77-81.
13
Li G, Wang H, Gao Y, Cui X, Zhang G. Primary abdominopelvic desmoplastic small round cell tumor: CT and correlated clinicopathologic features. Eur Rev Med Pharmacol Sci 2014;18(18):2670-7.
14
Hirano G, Irie M, Nakashima Y, Shakado S, Sohda T, Tanaka T, et al. Desmoplastic small round cell tumors in a young man. Intern Med 2012;52(17):1909-14.
15
Devoe K, Weidner N, editors. Immunohistochemistry of small round-cell tumors. Semin Diagn Pathol 2000;17:216-24.
16
Goodman K A, Wolden S L, LaQuaglia M P, & Kushner B H. Whole abdominopelvic radiation therapy for desmoplastic small round-cell tumor. Int J Radiat Oncol Biol Phys 2001; 51(3), 118-9.
17
ORIGINAL_ARTICLE
Round Ligament Leiomyoma Developing During Pregnancy: A Case Report and Literature Review
Round ligament leiomyoma of uterus is rare. It can be presented as inguinal swelling mimicking the inguinal hernia or lymph node. Surgical excision is its curative treatment. Definitive diagnosis is made by histopathological examination. A 32 year old pregnant patient having round ligament leiomyoma as diagnosed histopathologically in Recep Tayyip Erdogan University Hospital in 2014 was presented here as the sixth case in literature.
https://ijp.iranpath.org/article_19730_f99072642f7cd3afaf9a8c1a33dd5bdf.pdf
2016-07-01
261
264
Leiomyoma
Pregnant
Inguinal mass
Recep
Bedir
bedirrecep@gmail.com
1
Dept. of Pathology, Recep Tayyip Erdogan University School of Medicine, Rize, Turkey
LEAD_AUTHOR
Rukiye
Yilmaz
dr.rukiyeyilmaz@gmail.com
2
Dept. of Pathology, Recep Tayyip Erdogan University School of Medicine, Rize, Turkey
AUTHOR
İbrahim
Sehitoglu
sehitogluibrahim@gmail.com
3
Dept. of Pathology, Recep Tayyip Erdogan University School of Medicine, Rize, Turkey
AUTHOR
Cuneyt
Yurdakul
cuneytyurdakul@yahoo.com
4
Dept. of Pathology, Recep Tayyip Erdogan University School of Medicine, Rize, Turkey
AUTHOR
Birge O, Arslan D, Kinali E, Bulut B. Round ligament of uterus leiomyoma: an unusual cause of dyspareunia. Case Rep Obstet Gynecol 2015; 2015: 197842.
1
Canto MJ, Palmero S, Palau J, Ojeda F. Laparoscopic management of a leiomyoma of the round ligament. J Obstet Gynaecol 2015; 18:1. [Epub ahead of print]
2
Colak E, Ozlem N, Kesmer S, Yildirim K. A rare inguinal mass: Round ligament leiomyoma. Int J Surg Case Rep 2013; 4(7): 577-8.
3
Ali SM, Malik KA, Al-Qadhi H, Shafiq M. Leiomyoma of the Round Ligament of the Uterus: Case report and review of literature. Sultan Qaboos Univ Med J 2012; 12(3): 357-9.
4
Pozzi PC. Leiomyoma of the round ligament complicating pregnancy. Riv Ostet Ginecol Prat 1957; 39(6): 549-59.
5
Kelly EG, Babiker M, Meshkat B, Beggan C, Leen E, Keeling P. An unusual finding in the inguinal canal of a 26-week pregnant patient. Hernia 2013; 17(4): 537-40.
6
Meen E, Vergis A. Rare cause of an inguinal mass in pregnancy. Can J Surg 2008; 51(6): E124.
7
Sciannameo F, Madami G, Madami C et al. Torsion of uterine fibroma associated with incarcerated inguinal hernia in pregnancy. Case report. Minerva Ginecol 1996; 48(11): 501-4.
8
Sherer DM, Edgar DM, Pulli GJ, Scibetta JJ. Pedunculated uterine fibroid simulating an incarcerated inguinal hernia in pregnancy. Am J Obstet Gynecol 1994; 170(3): 724-5.
9
David MW, Stanley RM. Leiomyoma of extraperitoneal round ligament: CT demonstration. Clin Imaging 1999; 23(6): 375-6.
10
Rein MS, Barbieri RL, Freidman AJ. Progesterone: A critical role in the pathogenesis of uterine myomas. Am J Obstet Gynecol 1995; 172(1): 14-8.
11
Smith P, Heimer G, Norgren A, Ulmsten U. The round ligament: A target organ for steroid hormones. Gynecol Endocrinol 1993; 7(2): 97-100.
12
Harish H, Sowmya NS, Indudhara PB. A rare case of round ligament leiomyoma:an inguinal mass. J Clin Diagn Res 2014; 8(10): NJ05-6.
13
Bhosale PR, Patnana M, Viswanathan C, Szkalaruk J. The inguinal canal: anatomy and imaging features of common and uncommon masses. Radiographics 2008; 28(3): 819-35.
14
ORIGINAL_ARTICLE
Association of Macrophage Activating Syndrome with Castleman’s Syndrome in Systemic Lupus Erythematosus
Macrophage Activating Syndrome (MAS) is a life-threatening disease seen in autoimmune diseases including lupus erythematosus, rheumatoid arthritis, Still's disease, polyarteritis nodosa. It is characterized by fever, pancytopenia, liver failure, coagulopathy, and neurologic symptoms and high serum ferritin. A 27 yr. old female patient was admitted in shahid Mostafa Khomeini Hospital (Tehran-Iran) in May 2011 because of lower extremities edema and ascites and fever from 1.5 month ago. In physical examinations she had generalized lymphadenopathy, splenomegaly and pleural effusion. In laboratory tests she had pancytopenia, positive ANA and Anti DNA (ds), hypocomplementemia, hypertriglyceridemia and high ferritin level. Gradually she had signs of RPGN and ARDS. The patient had no skin and musculoskeletal signs of SLE and no liver failure nor coagulopathy of MAS. Her lymph node biopsy was reported as Castleman syndrome. Unlike other studies, the patient showed MAS before treatment with cytotoxic for lupus nephritis.
https://ijp.iranpath.org/article_19731_8a47519907700d0a2ce190df9f7b3c45.pdf
2016-07-01
265
271
Systemic Lupus Erythematosus
Macrophage activating syndrome hemophagocytic lymphohistiosytosis
Castleman syndrome
Shamsa
Shariatpanahi
shariat15@yahoo.com
1
Dept. of Internal Medicine, Shahed University, Tehran, Iran
AUTHOR
Shahryar
Pourfarzam
shahr773@hotmail.com
2
Dept. of Pathology, Shahed University, Tehran, Iran
LEAD_AUTHOR
Mohammad hosein
Gheini
ghaini46@yahoo.com
3
Dept. of Pathology, Shahed University, Tehran, Iran
AUTHOR
ORIGINAL_ARTICLE
Cytodiagnosis of Chondromyxoid Fibroma of the Metatarsal Head: A Case Report
Chondromyxoid fibroma (CMF) is a rare benign cartilaginous tumor with a predilection for the bones of lower extremities and about one fourth of the tumors involve the foot.Radiologically, an eccentric lytic lesion with well defined margins is seen in the metaphysis of the bone. We hereby, report an 18 yr old young male who presented to Orthopedic Outpatient Department, JN Medical College, Aligarh Muslim University, India diagnosed with giant cell tumor of thethird metatarsal bone of right foot on radiography but on fine needle aspiration cytology (FNAC) the diagnosis of CMF was made. Preoperative diagnosis of this benign condition helped in doing minimum surgical intervention in the form of curettage along with bone grafting. Histopathology further confirmed the diagnosis of CMF. The case is being discussed to highlight the importance of FNAC to diagnose these uncommon benign bone lesions.
https://ijp.iranpath.org/article_19732_8cee28d256ab4e0da58bc6580c75b4fd.pdf
2016-07-01
272
275
Chondromyxoid fibroma (CMF)
Cytodiagnosis
Metatarsal bone
Bushra
Siddiqui
bushrasiddiqui85@yahoo.com
1
Dept. of Pathology, JN Medical College, Aligarh Muslim University, Aligarh, Uttar Pradesh, India
AUTHOR
Shahbaz
Habib Faridi
shahbazfaridi@yahoo.com
2
Dept. of Surgery, JN Medical College, Aligarh Muslim University, Aligarh, Uttar Pradesh, India
LEAD_AUTHOR
Mohd
Faizan
mohdfaizan2002@gmail.com
3
Dept. of Orthopaedics, JN Medical College, Aligarh Muslim University, Aligarh, Uttar Pradesh, India
AUTHOR
Syed
Ahmad
drshahbazfaridi@gmail.com
4
Department of Pathology, JN Medical College, Aligarh Muslim University, Aligarh, Uttar Pradesh, India.
AUTHOR
Rana
K Sherwani
drranak_sherwani65@yahoo.com
5
Dept. of Pathology, JN Medical College, Aligarh Muslim University, Aligarh, Uttar Pradesh, India
AUTHOR
Handa U, Bal A, Mohan H, Bhardwaj S. Fine needle aspiration cytology in the diagnosis of bone lesions.Cytopathology 2005; 16:59–64.
1
Walke VA, Nayak SP, Munshi MM, Bobhate SK. Cytodiagnosis of chondromyxoid fibroma. J Cytol 2010; 27:96-8.
2
Layfield LJ, Ferreiro JA. Fine needle aspiration cytology of chondromyxoid fibroma: a case report. DiagnCytopathol 1988;4:148–51.
3
Nielsen GP, Layfield LJ, Rosenberg AE. Neoplastic and tumor like lesion of bone. In: Silverberg SG, editor. Silverbergs principles and practice of surgical pathology and cytopathology. 4th ed. Philadelphia: Churchill Livingstone; 2006. pp. 701–83.
4
Jaffe HL, Linchtenstein L. Chondromyxoid fibroma of bone; a distinctive benign tumor likely to be mistaken especially for chondrosarcoma. Arch Pathol (Chic) 1948;45:541–51.
5
Daneshbod Y, Khademi B. Chondromyxoid fibroma of the mandible: A diagnostic pitfall on aspiration cytology of Parotid. ActaCytol 2008;52:636–8.
6
Wolf DA, Chaljub G, Maggo WG, Gelman BB. Intracranial chondromyxoid fibroma. Report of a case and review of literature. Arch Pathol Lab Med1997;121:626–30.
7
Dürr HR, Lienemann A, Nerlich A, Stumpenhausen B, Refior HJ. Chondromyxoid fibroma of bone. Arch Orthop Trauma Surg 2000; 120(1-2):42-7.
8
Greenspan A (1989) Tumors of cartilage origin. OrthopClin North Am 1989; 20 :347–366.
9
Feit EM, Dobbs BM. Chondromyxoid fibroma of the fourth metatarsal. J Am Podiatr Med Assoc 2000 Apr;90(4):211-6.
10
Goldenhar AS, Neil J, Whittaker S. Chondromyxoid fibroma of a metatarsal and cuneiform.J Am Podiatr Med Assoc 1994; 84(8):413-5.
11
Hazarika D, Kumar RV, Ramarao C, Mukherjee G, Pattabhirama V, ChadraShekhar M. Fine needle aspiration cytology of chondroblastoma and chondromyxoid fibroma: A report of 2 cases. Acta Cytol 1995;38:592–6.
12
Gupta S, Dev G, Marya S. Chondromyxoid fibroma: A fine- needle aspiration diagnosis. DiagnCytopathol 1993;9:63–5.
13
De Las Casas LE, Singh HK, Halliday BE, Xuf, Strausbauch PH, Silverman JF. Myxoid chondrosarcoma of sphenoid sinus and chondromyxoid fibroma of iliac bone: cytomorphologic findings of two distinct and uncommon myxoid lesion. Diagn Cytopathol 2000; 22:383–9.
14
Bhamra JS, Al-Khateeb H, Dhinsa BS, Gikas PD, Tirabosco R, Pollock RC et al. Chondromyxoid fibroma management: a single institution experience of 22 cases. World J Surg Oncol 2014 Sep 12; 12:283.
15
ORIGINAL_ARTICLE
Multifocal Central Giant Cell Granuloma - A Case Report
Central giant cell granuloma is a benign, aggressive neoplasm composed of multinucleated giant cells that almost exclusively occurs in the jaws though extra-gnathic incidence is rare.Multifocal CGCGs of the jaws are very rare and suggestive of systemic diseases such as hyperparathyroidism,an inherited syndrome such as Noonan-like multiple giant cell lesion syndrome or other disorders.Very few cases of multifocal CGCGs in the jaws without any concomitant systemic disease have been reported. This paper describes an unusual case reported to the Oral Surgery Department of Dr. D.Y.Patil Dental College & Hospital, Nerul, Navi-Mumbai in 2014ina45-year-old male with multifocal central giant cell granuloma involving maxilla and mandible. The serum alkaline phosphatase, calcium and phosphorus levels were within the normal limits. After complete clinical examination hyperparathyroidism and clinical characteristic of any syndromes such as Noonan-like syndrome and neurofibromatosis were ruled out. Thus this paper reports a non-syndromic multifocal central giant cell granuloma.
https://ijp.iranpath.org/article_19733_9113cc150f224878b70c1a476d879730.pdf
2016-07-01
276
280
Giant cell
Hyperthyroidism
Multifocal
Syndromes
Maxilla
Mandible
Tamgadge
Sandhya
avinash.pt@gmail.com
1
Dept. of Oral & Maxillofacial Pathology and Microbiology Dr D Y Patil Dental College & Hospital, Sector 7, Nerul, Navi Mumbai, Maharashtra, India.
AUTHOR
Tamgadge
Avinash
sandhya.tamgadge@gmail.com
2
Dept. of Oral & Maxillofacial Pathology and Microbiology Dr D Y Patil Dental College & Hospital, Sector 7, Nerul, Navi Mumbai, Maharashtra, India.
LEAD_AUTHOR
Dhauskar
Snehal
snehal0489@gmail.com
3
Dept. of Oral & Maxillofacial Pathology and Microbiology Dr D Y Patil Dental College & Hospital, Sector 7, Nerul, Navi Mumbai, Maharashtra, India.
AUTHOR
Tiwari
Neha
drneha.1188@yahoo.com
4
Dept. of Oral & Maxillofacial Pathology and Microbiology Dr D Y Patil Dental College & Hospital, Sector 7, Nerul, Navi Mumbai, Maharashtra, India.
AUTHOR
Mudaliar
Uma
uma.nm88@gmail.com
5
Dept. of Oral & Maxillofacial Pathology and Microbiology Dr D Y Patil Dental College & Hospital, Sector 7, Nerul, Navi Mumbai, Maharashtra, India.
AUTHOR
Vered M, Buchner A, Dayan D. Central giant cell granuloma of the Jaw bones – new insights into molecular biology with clinical implications on treatment approaches. Histol. Histopathol 2008;23:1151-60.
1
Kaffe I, Ardekian L, Taicher S, Littner MM, Buchner A. Radiologic features of central giant cell granuloma of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996;81(6):720-6.
2
Devi P, T Swaroopkanth, G Sudhakar, D Kiranmai, R Sasank, D Sridharreddy et al. Central Giant Cell Granuloma of Maxilla: A Case Report. Indian J Otolaryngol Head Neck Surg.2013;65(Suppl1):S192-4.
3
Miloro M, Quinn PD. Synchronous Central Giant Cell Lesions of the Jaws: Report of a Case and Review of the Literature.J.Oral Maxillofacial Surg995;53:1350-55.
4
Bilodeau E, Chowdhury K, Collins B. A Case of Recurrent: Multifocal Central Giant Cell Granulomas. Head and Neck Pathol 2009;3:174-78.
5
Cossio P, Fuentes R,Carranza A,Lagares D, Jose P. Recurrent central giant cell granuloma in the mandible: Surgical treatment and dental implant restoration. Med Oral Patol Oral Cir Bucal 2007;12:E229-30.
6
Donoff RB, Rosenberg AE. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 20-1993. A 23-year-old woman with a rapidly enlarging intraoral mass after a tooth extraction. N Engl J Med. 1993;328(20):1478-83.
7
Jadu F, Pharoah M, Lee L, Baker GL, Allidina A. Central giant cell granuloma of the mandibular condyle: a case report and review of the literature. Dentomaxillofac Radiol 2011;40 (1):60-64.
8
Noleto J, Marchiori E, Sampaio R, Irion K, Collares F. Radiological and epidemiological aspects of central giant cell granuloma. Radiol Bras 2007;40(3):167-171
9
Edwards P, Fox J, Fantasia J, Golberg J, Kelsch R.Bilateral central giant cell granulomas of the mandible in an 8-year-old girl with Noonan syndrome (Noonan-like/multiple giant cell lesion syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005 April;99(3):334-40.
10
Soundarya N, Sharada P,Nilima P, GL Pradeep.Bilateral maxillary brown tumors in a patient with primary hyperparathyroidism: Report of a rare entity and review of literature. J Oral Maxillofac Pathol. 2011 Jan-April;15(1):56-59.
11
ORIGINAL_ARTICLE
Meningeal Hemangiopericytoma in 33-Year-Old Female; a Case Report
Intracranial hemangiopericytomas (HPC) are rare vascular tumors. They account for 0.4% of primary central nervous system tumors. HPC is more commonly located supratentorially and tends to occur in a younger age group, with average age at presentation of 38–42 years. The tumor was found throughout the entire CNS, usually superficially and closely related to the meninges. Moreover, they have a strong tendency for local recurrence and extracranial metastasis. Given the clinical, pathological and imaging similarities between Hemangiopericytoma and angioblastic/anaplastic meningioma and the necessity of differentiating these two (choosing the proper treatment and prognosis), we present a report of meningeal Hemangiopericytoma tumor in a 33-year-old female. Our study suggests that in addition to routine histopathological examination, immunohistochemical study is essential to differentiate it from other differential diagnosis. How to cite this article: Abdollahi A, Abdollahpouri R,Tavangar SM. Meningeal Hemangiopericytoma in a 33-yr-Old Female; a Case Report. Iran J Pathol. 2016; 11(3):281-5.
https://ijp.iranpath.org/article_19734_00f7f8cf0a4c02ce38f213fc5590db90.pdf
2016-07-01
281
285
Meningeal Hemangiopericytoma
Intracranial Tumors
Alireza
Abdollahi
dr_p_abdollahi@yahoo.com
1
Dept. of Pathology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Reyhaneh
Abdollahpouri
reihaneh.abdollahpouri@gmail.com
2
Dept. of Pathology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Seyed-Mohammad
Tavangar
tavangar@ams.ac.ir
3
Dept. of Pathology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
LEAD_AUTHOR
Stout AP, Murray MR. Hemangiopericytoma. a vascular tumor featuring Zimmermann's pericyts. Ann Surg 1942; 116(1):26-33.
1
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114(2):97-109.
2
Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain mours. Brain Pathol 1993; 11:255–68.
3
Mena H, Ribas JL, Pezeshkpour GH, Cowan DN, Parisi JE. Hemangiopericytoma of the central nervous system: a review of 94 cases. Hum Pathol 1991; 11:84–91.
4
Perry A ,Scheithauer BW , Nascimento AG . The immunophenotypic spectrum of meningeal hemangiopericytoma: a comparison with fibrous meningioma and solitary fibrous tumor of meninges . Am J Surg Pathol 1997; 21 ( 11 ): 1354 – 60 .
5
Liu G , Chen ZY , Ma L , Lou X , Li SJ , Wang YL . Intracranial hemangiopericytoma: MR imaging findings and diagnostic usefulness of minimum ADC values. J Magn Reson Imaging 2013;38(5):1146-51.
6
Guthrie BL, Ebersold MJ, Scheithauer BW, Shaw EG. Meningeal hemangiopericytoma: histopathological features, treatment, and long-term follow-up of 44 cases. Neurosurgery 1989; 25:514–22.
7
Jääskeläinen J, Servo A, Haltia M, Wahlström T, Valtonen S. Intracranial emangiopericytoma: radiology, surgery, radiotherapy, and outcome in 21 patients. Surg Neurol 1985;23:227–36.
8
Dufour H, Métellus P, Fuentes S, Murracciole X, Régis J, Figarella-Branger D, et al. Meningeal hemangiopericytoma: a retrospective study of 21 patients with special review of postoperative external radiotherapy. Neurosurgery 2001; 48:756–63.
9
Chiechi MV, Smirniotopoulos JG, Mena H. Intracranial hemangiopericytomas: MR and CT features. AJNR Am J Neuroradiol 1996; 17(7):1365-71.
10
Rajaram V, Brat DJ. Anaplastic meningioma versus meningeal hemangiopericytoma: immunohistochemical and genetic markers. Hum Pathol 2004; 35:1413–18.
11
Wei G, Kang X, Liu X, Tang X, Li Q, Han J,et al. Intracranial meningeal hemangiopericytoma: Recurrences at the initial and distant intracranial sites and extraneural metastases to multiple organs. Mol Clin Oncol 2015; 3(4):770-774.
12
Nakada S, Minato H, Takegami T, Kurose N, Ikeda H, Kobayashi M,et al. NAB2-STAT6 fusion gene analysis in two cases of meningeal solitary fibrous tumor/hemangiopericytoma with late distant metastases. Brain Tumor Pathol 2015 Apr 18.
13
Han N, Kim H, Min SK, Paek SH, Park CK, Choi SH,et al. Meningeal Solitary Fibrous Tumors with Delayed Extracranial Metastasis. J Pathol Transl Med 2015; 14.
14
Noh SH, Lim JJ, Cho KG. Intracranial Hemangiopericytomas : A Retrospective Study of 15 Patients with a Special Review of Recurrence. J Korean Neurosurg Soc 2015; 58(3):211-6.
15
Trabelsi S, Mama N, Chourabi M, Mastouri MH, Ladib M, Popov S,et al. Meningeal Hemangiopericytomas and Meningomas: a Comparative Immunohistochemical and Genetic Study. Asian Pac J Cancer Prev 2015;16(16):6871-6.
16
ORIGINAL_ARTICLE
A Tete – a – tete of benign, borderline and malignant fibrohistiocytic tumor
Dermatofibrosarcoma protruberans is a relatively uncommon slow growing, locally aggressive fibrous tumor of the skin. It has a prospensity of progressing to fibrosarcomatous change in 5% of the cases. We present a case of a 56 yr old male with presented to the outpatient department of surgery, Sri Siddhartha Medical College, Tumkur with a chest swelling in 2013. FNAC was inconclusive and the mass was excised. On histopathology, areas of benign fibrohistiocytic tumor, dermatofibrosarcoma protruberans and fibrosarcomatous dermatofibrosarcoma were identified in the same tumor. Immunohistochemistry confirmed the diagnosis of DFSP with fibrosarcomatous change. Although, transformed DFSP is more aggressive, the prognosis is influenced by the extent of excision and with wide excision, there may be little increased risk for recurrence and metastasis over that of conventional DFSP.
https://ijp.iranpath.org/article_19735_e23b9a5cae226d1516b9612dd4b3b10d.pdf
2016-07-01
286
290
Benign fibrohistiocytic tumor
Dermatofibrosarcoma protruberans
Fibrosarcomatous dermatofibrosarcoma protruberans
RASHMI
M.V.
rashmiarava@yahoo.com
1
Dept. of Pathology, Sri Siddhartha Medical College, Tumkur, Karnataka – 572104, India
LEAD_AUTHOR
Pavithra
P
drpavithra83@gmail.com
2
Dept. of Pathology, Sri Siddhartha Medical College, Tumkur, Karnataka – 572104, India
AUTHOR
Shivakumarappa
G.M.
drgeethajp@gmail.com
3
Dept. of Surgery, Sri Siddhartha Medical College, Tumkur, Karnataka – 572104, India
AUTHOR
Szollosi Z, Nemes Z. Transformed dermatofibrosarcoma protruberans: a clinicopathological study of eight cases. J Clin Pathol 2005; 58: 751-6.
1
Arican O, Bakaris S, Bulbuloglu E, Ezberci F. Myoid differentiation and EMA expression in fibrosarcomatous dermatofibrosarcoma protuberans. Acta Dermatoven APA 2006; 15(1): 39-44.
2
Prabhu R, Kumar N, Sadhu S, Shenoy R. Fibrosarcomatous dermatofibrosarcoma protruberans: A case report of an aggressive soft tissue sarcoma. J Clin Exp Res 2013; 1(3): 71-73.
3
Mentzel T, Beham A, Katenkamp D, Dei Tos AP, Fletcher CD. Fibrosarcomatous (“high grade”) dermatofibrosarcoma protuberans : Clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance. Am J Surg Pathol 1998; 22(5): 576-87.
4
Angouridakis N, Kafas P, Jerjes W et al. Dermatofibrosarcoma protruberans with fibrosarcomatous transformation of head and neck. Head Neck Oncol 2011; 3: 5.
5
Kerob D, Pedeutour F, Leboeuf C et al. Value of cytogenetic analysis in treatment of dermatofibrosarcoma protruberans. JCO 2008; 26(10): 1757-9.
6
Serra – Guillen C, Llombart B, Sanmartin O lDermatofibrosarcoma protruberans. Actas Dermosifiliogr 2012; 103: 762-77.
7
Kim SJ, Jung HK, Kim KI. Axillary metastasis in abdominal dermatofibrosarcoma protruberans with the fibrosarcomatous changes: A case report. J Korean Soc Radiol 2013; 68(5): 417-21.
8
Szollosi Z, Scholtz B, Egervari K, Nemes Z. Transformed dermatofibrosarcoma protruberans: real time polymerase chain reaction of COL1A1-PDGFB fusion transcripts in sarcomatous areas. J Clin Pathol 2007; 60: 190-4.
9
Campos M, Zarco C, Acquadro F. Myxoid dermatofibrosarcoma protruberans in childhood. Actas Dermosifiliogr 2012; 103: 422-6.
10
Palmerini E, Gambarotti M, Staals EL et al. Fibrosarcomatous changes and expression of CD34+ and apolipoprotein – D in dermatofibrosarcoma protuberans. Clinical Sarcoma Research 2012; 2: 4.
11
Asuquo ME, Umoh MS, Ebughe G. Dermatofibrosarcoma protruberans: case reports. Ann Afr Med 2007; 6(2): 80-3.
12
Edelweiss M, Malpica A. Dermatofibrosarcoma protruberans of the vulva: A clinicopathologic and immunohistochemical study of 13 cases. Am J Surg Pathol 2010; 34: 393-400.
13
Gupta AK, Singh H, Manalel AM, Jaiswal NK. A rare case of scalp dermato-fibrosarcoma-protruberans with intracranial extension and distant soft tissue and liver metastasis. Calicut Med J 2011; 9(2): 8-11.
14
ORIGINAL_ARTICLE
Meningioangiomatosis in an otherwise healthy 13 year-old boy: A case report with emphasis on histopathological findings
Meningioangiomatosis is regarded as a rare benign hamartomatous condition mostly involving the cerebral cortex and overlying leptomeninges. A strong association of MA with neurofibromatosis type 2 has been documented in published articles. Herein we report a case of an otherwise healthy 13-year-old boy with no family history or stigmata of neurofibromatosis who presented with intractable seizures. MRI revealed a 2x2 cm mass lesion in the frontal lobe. The patient underwent complete surgical resection of the lesion. Although the primary radiologic impression of the lesion was glioma, pathological evaluation of the resected specimen showed mainly proliferation of meningothelial cells and fibroblast-like cells with many thickened blood vessels, which are typical for diagnosis of meningioangiomatosis. After surgical removal of the lesion, the patient is free of seizures. How to cite this article: Motevalli D, Kamalian N, Tavangar SM. Meningioangiomatosis in an otherwise healthy 13 year-old boy: A case report with emphasis on histopathological findings. Iran J Pathol. 2016;11(3):291-5.
https://ijp.iranpath.org/article_20532_3e1c87adf80a9143d27c061ac88f5770.pdf
2016-07-01
291
295
Meningioangiomatosis
sporadic
Seizure
Histopathology
Dorna
Motevalli
dmotevalli@yahoo.com
1
Dept. of Pathology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Naser
Kamalian
kamalian@tums.ac.ir
2
Dept. of Pathology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Seyed Mohammad
Tavangar
tavangar@ams.ac.ir
3
Dept. of Pathology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
LEAD_AUTHOR
Arcos A, Serramito R, Santin JM, Prieto A, Gelabert M, Rodriguez-Osorio X, et al. Meningioangiomatosis: clinical-radiological features and surgical outcome. Neurocirugia 2010;21(6):461-6.
1
Cui H, Shi H, Chen X, Wang W, Lai R, Han A. Clinicopathological Features of Meningioangiomatosis Associated with Meningioma: A Case Report with Literature Review. Case Rep Oncol Med 2012;2012:5.
2
Abdulazim A, Samis Zella MA, Rapp M, Gierga K, Langen KJ, Steiger HJ, et al. Meningioangiomatosis in a patient with progressive focal neurological deficit-case report and review of literature. BRIT J NEUROSURG 2013;27(2):253-5.
3
Sun Z, Jin F, Zhang J, Fu Y, Li W, Guo H, et al. Three cases of sporadic meningioangiomatosis with different imaging appearances: case report and review of the literature. World J Surg Oncol 2015;13:89.
4
Bassoe P, Nuzum F. Report of a case of central and peripheral neurofibromatosis. J Nerv Ment Dis 1915; 42: 785–96
5
Worster-Drought, C. , W. E. C. Dickson , and W. H. McMenemey . Multiple meningeal and perineural tumours with analogous changes in the glia and ependymal (neurofibroblastomatosis). Brain 1937. 60:85–117.
6
Savargaonkar P, Chen S, Bhuiya T, Valderrama E, Bloom T, Farmer PM. Meningioangiomatosis: report of three cases and review of the literature. Ann Clin Lab Sci 2003;33(1):115-8.
7
Omeis I, Hillard VH, Braun A, Benzil DL, Murali R, Harter DH. Meningioangiomatosis associated with neurofibromatosis: report of 2 cases in a single family and review of the literature. Surg neurol 2006; 65(6):595-603.
8
Halper J, Scheithauer BW, Okazaki H, Laws ER, Jr. Meningio-angiomatosis: a report of six cases with special reference to the occurrence of neurofibrillary tangles. J Neuropathol Exp Neurol 1986;45(4):426-46.
9
Dumanski JP, Rouleau GA, Nordenskjold M, Collins VP. Molecular genetic analysis of chromosome 22 in 81 cases of meningioma. Cancer Res 1990;50(18):5863-7.
10
Cui H, Shi H, Chen X, Wang W, Lai R, Han A. Clinicopathological features of meningioangiomatosis associated with meningioma: a case report with literature review. Case Rep Oncol Med 2012;2012:296286.
11
Li J, Song X, Gui Q. [Meningioangiomatosis: a clinicopathological study of five cases]. Zhonghua Bing Li Xue Za Zhi. 2015 May;44(5):310-4.
12
Ishihara M, Miyagawa-Hayashino A, Nakashima Y, Haga H, Takahashi JA, Manabe T. Intracerebral schwannoma in a child with infiltration along perivascular spaces resembling meningioangiomatosis. Pathol Int 2009 Aug;59(8):583-7.
13
Sun Z, Jin F, Zhang J, Fu Y, Li W, Guo H, et al. Three cases of sporadic meningioangiomatosis with different imaging appearances: case report and review of the literature. World J Surg Oncol 2015; 13: 89.
14
Kunishio K, Yamamoto Y, Sunami N, Satoh T, Asari S, Yoshino T, et al. Histopathologic investigation of a case of meningioangiomatosis not associated with von Recklinghausen's disease. Surgical neurology 1987;27(6):575-9.
15
ORIGINAL_ARTICLE
Spinal Intradural Extramedulary Capillary Hemangioma Mimicking Meningioma
Hemangiomas are considered as vascular malformations which are categorized by the type of vascular channel to capillary, cavernous, venous or arteriovenous(1). Their usual locations are soft tissue , cutaneous or subcutaneous tissue and bone especially vertebra(2).However, intradural extramedullary hemangiomas are rare and most of them fall in cavernous type category. Hereby, authors report a woman with spinal intradural extramedullary capillary hemangioma which is exceedingly rare.
https://ijp.iranpath.org/article_19737_0013bbf39b95a3b9cb02c91332cfd662.pdf
2016-07-01
296
297
intradural tumor
capillary hemangioma
Moeinadin
Safavi
moein.safavi@gmail.com
1
Dept. of Pathology, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran
LEAD_AUTHOR
Shahriar
Dabiri
dabiri12@yahoo.com
2
Dept. of Pathology, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Vassal F, Péoc’h M, Nuti C. Epidural capillary hemangioma of the thoracic spine with proximal nerve root involvement and extraforaminal extension. Acta Neurochirurgica 2011;153(11):2279-81.
1
Shin JH, Lee HK, Jeon SR, Park SH. Spinal intradural capillary hemangioma: MR findings. Am J Neuroradiol 2000;21(5):954-6.
2
Takata Y, Sakai T, Higashino K, Goda Y, Tezuka F, Sairyo K. Intradural Extramedullary Capillary Hemangioma in the Upper Thoracic Spine: A Review of the Literature. Case reports in Orthopedics. 2014;2014.
3
Nowak DA, Widenka DC. Spinal intradural capillary haemangioma: a review. Eur Spine J 2001;10(6):464-72.
4
Abdullah DC, Raghuram K, Phillips CD, Jane JA, Miller B. Thoracic intradural extramedullary capillary hemangioma. Am J Neuroradiol 2004;25(7):1294-6.
5
ORIGINAL_ARTICLE
Bilateral Cervical Lymphadenopathy- Need to Think Beyond Tuberculosis
Any patient with bilateral lymphadenopathy especially in Indian subcontinent is regarded as suffering from tuberculosis unless proved otherwise. This sometimes leads to unwarranted delay in correct diagnosis and management if there is ignorance regarding other rarer etiologies. Rosai-Dorfman Disease (RDD) may present in the same manner and should always be kept on the back of the mind to help avoid unnecessary empirical anti-tuberculous therapy that is usually prescribed in so called difficult-to-diagnose tuberculosis infections.
https://ijp.iranpath.org/article_19738_a541623f59b2965f4c29976f5e49c0f4.pdf
2016-07-01
298
300
Rosai-Dorfman disease
tuberculosis
Lymphadenopathy
Rupali
Malik
drvickyster@gmail.com
1
Department of Internal Medicine, VMMC and Safdarjang Hospital, New Delhi-110029, India
LEAD_AUTHOR
Nisha
Rana
nisharana@gmail.com
2
Department of Pathology, VMMC and Safdarjang Hospital, New Delhi-110029, India
AUTHOR
Rosai J, Dorfman RF. Sinus histiocytosis with massive lymphadenopathy: A newly recognised benign clinicopathological entity. Arch Pathol 1969;87:63-70
1
Chandrashekhara SH, Manjunatha YC, Muzumder S, Bahl A, Das P, Suri V et al. Multicentric sinus histicytosis (Rosai-Dorfman Disease): Computed tomography, magnetic resonance imaging findings. Indian J Med Paediatr Oncol 2011; 32:174-6
2
Foucar E, Rosai J, Dorfman R. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman Disease): Review of the entity. Semin Diagn Pathol 1990; 7:19-73.
3
Jani PA, Banjan D. A case of Sinus Histiocytosis with Massive Lymphadenopathy (Rosai- Dorfman Syndrome) from Western India. Mcgill J Med 2008 11(2):156-59.
4
Foucar E, Rosai J, Dorfman RE. Sinus Histiocytosis with massive lymphadenopathy: an analysis of 14 deaths occurring in a patient registry. Cancer 1984; 54: 1834-40.
5
ORIGINAL_ARTICLE
Pregnancies Complicated by Hemoglobin H disease
Dear Editor-in-Chief The recent report on “The Adverse Effects of Pregnancies Complicated by Hemoglobin H (HBH) Disease” is very interesting (1). Rabiee et al. reported a pregnant case complicated with HBH disease. Indeed, this problem might not common in the Middle East but it is very common in Southeast Asia. The authors hereby would like to share the experience on this topic. In the recent report by Tongsong et al. (2), the maternal outcomes of normal mothers and those with HBH disease were not different. The common identified problems are fetal growth restriction, preterm birth and low birth weight (2).
https://ijp.iranpath.org/article_19739_f8ac8af9767525bbb2e46861c972117e.pdf
2016-07-01
301
302
Pregnancy
Hemoglobin H disease
Beuy
Joob
beuyjoob@hotmail.com
1
Medical Academic Center, Bangkok, Thailand
LEAD_AUTHOR
Viroj
Wiwanitkit
wviroj@yahoo.com
2
Faculty of Medicine, University of Nis, Serbia Bangkok, Thailand.
AUTHOR
Rabiee M, Shams JA, Zafargandie N. The Adverse Effects of Pregnancies Complicated by Hemoglobin H (HBH) Disease. Iran J Pathol 2015 Fall;10(4):318-21.
1
Tongsong T, Srisupundit K, Luewan S. Outcomes of pregnancies affected by hemoglobin H disease. Int J Gynaecol Obstet 2009 Mar;104(3):206-8.
2
Wiwanitkit V, Suwansaksri J, Paritpokee N. Combined one-tube osmotic fragility (OF) test and dichlorophenol-indolphenol (DCIP) testscreening for hemoglobin disorders, an experience in 213 Thai pregnant women. Clin Lab 2002;48(9-10):525-8.
3
Jaovisidha A, Ajjimarkorn S, Panburana P, Somboonsub O, Herabutya Y, Rungsiprakarn R. Prevention and control of thalassemia in Ramathibodi Hospital, Thailand. Southeast Asian J Trop Med Public Health 2000 Sep;31(3):561-5.
4
Taweevisit M, Thorner PS. Hydrops fetalis in the stillborn: a series from the central region of Thailand. Pediatr Dev Pathol 2010 Sep-Oct;13(5):369-74.
5
Insiripong S, Prabriputaloong S, Wisanuyothin N. Thalassemic mothers and their babies. Southeast Asian J Trop Med Public Health 2009 Mar;40(2):302-5.
6